Chimeric antigen receptor and methods of using it

专利摘要:

公开号:ES2758227T9
申请号:ES17187293T
申请日:2014-02-14
公开日:2020-05-12
发明作者:Chia-Yung Wu；James Onuffer；Wendell A Lim
申请人:University of California；
IPC主号:

专利说明:

[0001]
[0002] Chimeric antigen receptor and methods of using it
[0003]
[0004] Introduction
[0005]
[0006] In adoptive cell-based immunotherapy, immune cells isolated from the patient can be modified to express synthetic proteins that allow the cells to carry out new therapeutic functions after they have been transferred back to the patient. An example of such synthetic proteins is a chimeric antigen receptor (CAR). An example of a c Ar currently used is a fusion of an extracellular recognition domain (eg, an antigen binding domain), a transmembrane domain, and one or more intracellular signaling domains. Upon coupling with the antigen, the intracellular signaling portion of the CAR can initiate an activation-related response in an immune cell, such as the release of cytolytic molecules to induce death of tumor cells, etc. However, it is not possible to control these CARs from the pharmacological point of view. There is a need in the art for a conditionally activatable CAR that can be controlled pharmacologically.
[0007]
[0008] Summary
[0009]
[0010] The present disclosure provides a conditionally active heterodimeric chimeric antigen (CAR) receptor and a nucleic acid comprising a nucleotide sequence encoding CAR. The present disclosure provides genetically modified cells to produce CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
[0011]
[0012] Brief description of the drawings
[0013]
[0014] Figures 1A and 1B provide nucleotide and amino acid sequences of the domains of construct # 122.
[0015] Figures 2A and 2B provide nucleotide and amino acid sequences of the domains of construct # 123.
[0016] Figures 3A and 3B provide nucleotide and amino acid sequences of the domains of construct # 125.
[0017] Figure 4 provides nucleotide and amino acid sequences of domains of construction # 126. Figures 5A and 5B provide nucleotide and amino acid sequences of domains of construction # 168.
[0018] Figures 6A-C provide nucleotide and amino acid sequences of the domains of construct # 169.
[0019] Figures 7A and 7B provide nucleotide and amino acid sequences of the domains of construct # 170.
[0020] Figures 8A and 8B provide nucleotide and amino acid sequences of the domains of construct # 197.
[0021] Figures 9A-C provide nucleotide and amino acid sequences of the domains of construct # 206.
[0022] Figures 10A and 10B provide nucleotide and amino acid sequences of the domains of construct # 207.
[0023] Figures 11A-C provide nucleotide and amino acid sequences of the domains of construct # 199.
[0024] Figure 12 illustrates IL-2 production triggered by five CAR active center variants.
[0025] Figure 13 illustrates IL-2 production by Jurkat control lines.
[0026] Figure 14 illustrates a comparison between the "122 206" and "197 206" CAR constructs.
[0027] Figure 15 illustrates the cytotoxicity data with the CAR active center "197 + 206."
[0028] Figure 16 illustrates the T lymphocyte activation data using the "122 199" CAR constructs; "197 199"; and "122 168".
[0029] Figure 17 is a schematic representation of an active CAR center.
[0030] Figures 18A and 18B illustrate various active centers of CAR.
[0031] Figures 19A-G illustrate IL-2 production triggered by 3 different variants of CAR active center that recognize human mesothelin.
[0032] Figures 20A-C illustrate IL-2 production triggered by a CAR active center variant with a dimerization pair sensitive to gibberellic acid.
[0033] Figures 21A-D illustrate exemplary CAR and CAR active centers with various costimulatory domains.
[0034] Figures 22A and 22B provide nucleotide and amino acid sequences of the domains of construct # 270.
[0035] Figures 23A and 23B provide nucleotide and amino acid sequences of the domains of construct # 300.
[0036] Figures 24A and 24B provide nucleotide and amino acid sequences of the construction domains. No. 336.
[0037] Figures 25A and 25B provide nucleotide and amino acid sequences of the domains of construct # 337.
[0038] Figures 26A and 26B provide nucleotide and amino acid sequences of the domains of construct # 357.
[0039] Figures 27A and 27B provide nucleotide and amino acid sequences of the domains of construct # 365.
[0040] Figures 28A and 28B provide nucleotide and amino acid sequences of the domains of construct # 366.
[0041] Figures 29A and 29B provide nucleotide and amino acid sequences of the domains of construct # 367.
[0042] Figures 30A and 30B provide nucleotide and amino acid sequences of the domains of construct # 398.
[0043] Figures 31A and 31B provide nucleotide and amino acid sequences of the domains of construct # 399.
[0044] Figures 32A and 32B provide nucleotide and amino acid sequences of the domains of construct # 400.
[0045] Figures 33A and 33B provide nucleotide and amino acid sequences of the domains of construct # 358.
[0046]
[0047] Definitions
[0048]
[0049] The terms "polynucleotide" and "nucleic acid", used interchangeably herein, refer to a polymeric form of nucleotides of any length, be they ribonucleotides or deoxyribonucleotides. Therefore, this term includes, but is not limited to, mono, bi or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer that contains puric and pyrimidine bases or other naturally-occurring, chemically modified, or nucleotide bases. biochemically, unnatural or derivatized.
[0050]
[0051] The terms "antibody" and "immunoglobulin" include antibodies or immunoglobulins of any isotype, fragments of antibodies that retain specific binding to the antigen, including, but not limited to, Fab, Fv, scFv and Fd fragments, chimeric antibodies, humanized antibodies, single chain antibodies and fusion proteins comprising an antigen-binding portion of an antibody and a protein that is not an antibody.
[0052] "Antibody fragments" comprise a portion of an intact antibody, eg, the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab ', F (ab') 2 and Fv fragments; diabodies; linear antibodies (Zapata et al., Protein Eng. 8 (10): 1057-1062 (1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site and a residual "Fc" fragment, a designation that reflects the ability to readily crystallize. Pepsin treatment produces an F (ab ') 2 fragment that has two antigen combining sites and is still capable of crosslinking with the antigen.
[0053]
[0054] Single chain Fv or "sFv" antibody fragments comprise the Vh and Vl domains of an antibody, where these domains are present on a single polypeptide chain. In some embodiments, the Fv polypeptide further comprises a polypeptide linker between the Vh and Vl domains, enabling the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pgs. 269-315 (1994).
[0055] As used herein, the term "affinity" refers to the equilibrium constant for reversible binding of two agents and is expressed as a dissociation constant (Kd). The affinity can be at least 1 times higher, at least 2 times higher, at least 3 times higher, at least 4 times higher, at least 5 times higher, at least 6 times higher, at least 7 times higher, at least 8 times higher, at least 9 times higher, at least 10 times higher, at least 20 times higher, at least 30 times higher, at least 40 times higher, at least 50 times higher, at least 60 times higher, at least 70 times higher, at least 80 times greater, at least 90 times greater, at least 100 times greater or at least 1000 times greater or more, than the affinity of an antibody for unrelated amino acid sequences. The affinity of an antibody for a target protein can be, for example, from about 100 nanomolar (nM) to about 0.1 nM, from about 100 nM to about 1 picomolar (pM), or from about 100 nM to about 1 femtomolar ( fM) or more. As used herein, the term "greed" refers to the resistance of a complex of two or more agents to dissociation after dilution. The terms "immunoreactive" and "preferentially binds" are used interchangeably herein for antibodies and / or antigen-binding fragments.
[0056]
[0057] The term "bond" refers to a direct association between two molecules, due to, for example, covalent, electrostatic, hydrophobic, and ionic and / or hydrogen bonding interactions, including interactions such as salt bridges and water bridges. Nonspecific affinity will refer to a binding with an affinity of less than about 10.7 M, eg, binding with an affinity of 10.6 M, 10.5 M, 10.4 M, etc.
[0058] As used herein, the term "hinge region" refers to a flexible linker polypeptide region (also referred to herein as "hinge" or "spacer") that provides flexibility and structural spacing to flanking polypeptide regions and it can consist of natural or synthetic polypeptides. An "hinge region" from an immunoglobulin (eg, IgG1) is generally defined as a series from Glu216 to Pro230 of human IgG1 (Burton (1985) Molec. Immunol., 22: 161-206). The hinge regions of other IgG isotypes can be aligned with the IgG1 sequence by placing the first and last cysteine residues that form disulfide (S-S) bonds between heavy chains at the same positions. The hinge region can be of natural or unnatural origin, including, but not limited to, an altered hinge region as described in US Patent No. 5,677,425. The hinge region may include a complete hinge region derived from an antibody of a different class or subclass than that of the CH1 domain. The term "hinge region" can also include regions derived from CD8 and other receptors that provide a similar function to provide flexibility and spacing to flanking regions.
[0059]
[0060] An "isolated" polypeptide is one that has been identified and separated and / or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that could interfere with the diagnostic or therapeutic uses of the polypeptide and may include enzymes, hormones, and other protein or non-protein solutes. In some embodiments, the polypeptide will be purified (1) by more than 90%, more than 95%, or more than 98%, by weight of antibody determined by the Lowry method, for example, more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by using a rotary cup sequencer or (3) until homogeneous by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ( SDS-PAGE) under reducing or non-reducing conditions using silver or Coomassie blue staining. An isolated polypeptide includes the polypeptide in situ with recombinant cells, as at least one component of the polypeptide's natural environment will not be present. In some cases, the isolated polypeptide will be prepared by at least one purification step.
[0061]
[0062] As used herein, the term "immune cells" generally includes white blood cells (leukocytes) that originate from hematopoietic stem cells (HSCs) produced in the bone marrow. "Immune cells" include, for example, lymphocytes (T lymphocytes, B lymphocytes, natural cytolytic (NK) lymphocytes) and cells of myeloid origin (neutrophils, eosinophils, basophils, monocytes, macrophages, and dendritic cells).
[0063]
[0064] "T lymphocyte" includes all types of immune cells that express CD3, including helper T lymphocytes (CD4 + cells), cytotoxic T lymphocytes (CD8 + cells), regulatory T lymphocytes (Treg), and gamma-delta T lymphocytes.
[0065] A "cytotoxic cell" includes CD8 + T lymphocytes, natural cytolytic lymphocytes (NK), and neutrophils, these cells being capable of mediating cytotoxicity responses.
[0066]
[0067] As used herein, the term "stem cell" generally includes pluripotent or multipotent stem cells. "Stem cells" include, for example, embryonic stem cells (ES); mesenchymal stem cells (MSC); induced pluripotent stem cells (iPS); and compromised progenitor cells (hematopoietic stem cells (HSC); cells from the bone marrow, etc.).
[0068]
[0069] As used herein, the terms "treatment", "treat" and the like, refer to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic in terms of completely or partially preventing a disease or a symptom thereof and / or it may be therapeutic in terms of a partial or complete cure for a disease and / or an adverse effect attributable to the disease. "Treatment", as used herein, encompasses any treatment of a disease in a mammal, eg, a human, and includes: (a) preventing the disease from occurring in a subject who may be predisposed to the disease, but which has not yet been diagnosed; (b) inhibit the disease, that is, stop its development; and (c) alleviating the disease, that is, causing the regression of the disease.
[0070]
[0071] The terms "individual", "subject", "host" and "patient", used interchangeably herein, refer to a mammal, including, but not limited to, murids (eg, rats, mice) , lagomorphs (eg rabbits), non-human primates, humans, canids, felids, ungulates (eg equidae, bovines, ovids, suidae, goats), etc.
[0072]
[0073] A "therapeutically effective amount" or "effective amount" refers to the amount of one agent or the combined amounts of two agents, which, when administered to a mammal or other subject to treat a disease, is sufficient to effect such treatment to the illness. The "therapeutically effective amount" will vary depending on the agents, the disease and its severity, and age, weight, etc. of the subject to be treated.
[0074] Before describing the present invention in more detail, it is to be understood that the present invention is not limited to the specific embodiments described, as these may obviously vary. It is also to be understood that the terminology used herein is for the sole purpose of describing the particular embodiments and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0075] In cases where a range of values is provided, it will be understood that the present invention encompasses each intermediate value, up to the tenth of the unit of the lower limit, unless the context clearly indicates otherwise, between the upper and lower limit of that range. and any other indicated or intermediate value within said range. The upper and lower limits of these smaller ranges may be included independently and are also included in the present invention, except for any limits specifically excluded in the range indicated. In cases where the indicated range includes one or both limits, ranges that exclude either or both of the included limits are also included in the invention.
[0076]
[0077] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as that normally understood by one of ordinary skill in the art to which this invention pertains. Although any methods and materials similar to those described herein may also be used in the practice or testing of the present invention, the preferred methods and materials are described below. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in relation to those cited in the publications.
[0078]
[0079] It should be noted that as used herein and in the appended claims, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise. Therefore, for example, reference to "a chimeric antigen receptor" includes various such chimeric antigen receptors and reference to "binding dimerizer pair" includes reference to one or more dimerizer binding pairs and equivalents thereof known by experts in the field and so on. It should also be noted that the claims can be drafted in such a way that they exclude any optional element. As such, this statement is intended to serve as a basis for the use of exclusive terminology such as "only", "only" and the like in connection with citing the elements of the claims or for the use of a "negative" limitation.
[0080] It will be appreciated that certain features of the invention, which, for clarity, are described in the context of separate embodiments, may also be provided in combination in a single embodiment. Rather, various features of the invention, which, for clarity, are described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments pertaining to the invention are specifically encompassed by the present invention and are disclosed herein as if each and every combination has been individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also encompassed by the present invention and are disclosed herein as if each and every such sub-combination has been individually and explicitly disclosed.
[0081]
[0082] The publications described herein are provided solely for disclosure prior to the filing date of this application. Nothing in this document should be construed as an admission that the present invention does not have the right to precede such publication by virtue of a prior invention. Also, the provided publication dates may differ from the actual publication dates, which might need to be independently confirmed.
[0083]
[0084] Detailed description
[0085]
[0086] The present disclosure provides a conditionally active heterodimeric chimeric antigen (CAR) receptor and a nucleic acid comprising a nucleotide sequence encoding CAR. The present disclosure provides genetically modified cells to produce CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
[0087]
[0088] CONDITIONALLY ACTIVE HETERODIMERIC CHEMICAL ANTIGEN RECEIVER.
[0089]
[0090] The present disclosure provides a conditionally active heterodimeric chimeric antigen receptor, which, for simplicity, is referred to herein as "CAR".
[0091]
[0092] In some embodiments, a CAR of the present disclosure comprises: a) a first polypeptide comprising: i) a member of a specific binding pair (eg, an antigen-binding domain); ii) a first modulator domain; iii) a first member of a dimerization pair; and iv) a transmembrane domain interposed between the member of a specific binding pair (eg, an antigen binding domain) and the first modulator domain; and b) a second polypeptide comprising: i) a transmembrane domain; ii) a second modulator domain; iii) a second member of the dimerization pair; and iv) an intracellular signaling domain. The modulator domain can be a costimulatory domain.
[0093]
[0094] In some embodiments, a CAR of the present disclosure comprises: a) a first polypeptide comprising: i) a member of a specific binding pair (eg, an antigen-binding domain); ii) a first costimulatory domain; iii) a first member of a dimerization pair (eg, a dimerizer binding pair); and iv) a transmembrane domain interposed between the member of a specific binding pair (eg, a binding domain to antigen) and the first costimulatory domain; and b) a second polypeptide comprising: i) a transmembrane domain; ii) a second costimulatory domain; iii) a second member of the dimerization pair (eg, the dimerizer binding pair); and iv) an intracellular signaling domain.
[0095]
[0096] In some embodiments, a CAR of the present disclosure comprises: a) a first polypeptide comprising: i) a member of a specific binding pair (eg, an antigen-binding domain); ii) a modulator domain; iii) a first member of a dimerization pair (eg, a dimerizer binding pair); iv) a transmembrane domain interposed between the member of a specific binding pair (eg, an antigen binding domain) and the modulator domain; and b) a second polypeptide comprising: i) a second member of the dimerization pair (eg, the dimerizer binding pair); and ii) an intracellular signaling domain. The modulator domain can be a costimulatory domain.
[0097]
[0098] In some embodiments, a CAR of the present disclosure comprises: a) a first polypeptide comprising: i) a member of a specific binding pair (eg, an antigen-binding domain); ii) a costimulatory domain; iii) a first member of a dimerization pair (eg, a dimerizer binding pair); iv) a transmembrane domain interposed between the member of a specific binding pair (eg, an antigen binding domain) and the costimulatory domain; and b) a second polypeptide comprising: i) a second member of the dimerization pair (eg, the dimerizer binding pair); and ii) an intracellular signaling domain.
[0099]
[0100] An example of a specific CAR is schematically represented in Figure 17. A CAR of the present disclosure may be present on the plasma membrane of a eukaryotic cell, eg, a mammalian cell, including, but not limited to, suitable mammalian cells, a cytotoxic cell, a T lymphocyte, a stem cell, the offspring of a stem cell, a progenitor cell, the offspring of a progenitor cell, and an NK cell. When present on the plasma membrane of a eukaryotic cell, a c A r of the present disclosure is active in the presence of: 1) a dimerizing agent that binds to the first and second members of the dimerizer binding pair in CAR or otherwise induces dimerization of the first and second members of the dimer; and 2) a factor that binds to the member of a specific binding pair (eg, an antigen-binding domain), eg, an antigen that binds to the antigen-binding domain of CAR. The factor that binds to the member of the specific binding pair is a second member of the specific binding pair. The second member of the specific binding pair may be a soluble factor (eg, not bound to a cell); a factor present on the surface of a cell, such as a target cell; a factor present on a solid surface; a factor present in a lipid bilayer; and the like. In cases where the member of a specific binding pair is an antibody and the second member of the specific binding pair is an antigen, the antigen may be a soluble antigen (eg, not bound to a cell); an antigen present on the surface of a cell, such as a target cell; an antigen present on a solid surface; an antigen present in a lipid bilayer; and the like.
[0101]
[0102] In some cases, a CAR of the present disclosure, when present in the plasma membrane of a eukaryotic cell, and when activated by a second member of a specific binding pair that binds to the member of the specific binding pair of CAR (by For example, an antigen that binds to the antigen binding domain of CAR) and a dimerizing agent, increases the expression of at least one nucleic acid in the cell. For example, in some cases, a CAR of the present disclosure, when present on the plasma membrane of a eukaryotic cell and when activated by an antigen that binds to the antigen-binding domain of CAR and a dimerization agent, increases expression of at least one nucleic acid in the cell by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times or more than 10 times, in comparison with the level of nucleic acid transcription in the absence of the antigen and / or the dimerizing agent.
[0103]
[0104] As an example, the second CAR polypeptide of the present disclosure may include an intracellular signaling polypeptide containing a tyrosine-based immunoreceptor (ITAM) activation motif; in such cases, a CAR of the present disclosure, when present in the plasma membrane of a eukaryotic cell and when activated by an antigen that binds to the antigen-binding domain of CAR and a dimerization agent, increases transcription-dependent of activated T lymphocyte nuclear factor (NFAT). NFAT dependent transcription includes transcription induced by any member of the NFAT family, including, for example, NFATc1, NFATc2, NFATc3, NFATc4, NFAT5; AP-1; Sp1; NKkB; and the like.
[0105]
[0106] A CAR of the present disclosure, when present in the plasma membrane of a eukaryotic cell and when activated by an antigen that binds to the antigen-binding domain of the CAR and a dimerization agent, may in some cases result , the increased production of one or more cytokines by the cell. For example, a CAR of the present disclosure, when present in the plasma membrane of a eukaryotic cell and when activated by an antigen that binds to the antigen-binding domain of the CAR and a dimerization agent, can increase the production of a cytokine by the cell in at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times or more than 10 times, compared to the amount of cytokines produced by the cell in the absence of the antigen and / or the dimerizing agent. Cytokines whose production can be increased include, but are not limited to, an interferon, eg IL-2, interferon gamma (IFN-y), tumor necrosis factor-alpha (TNF-a), IL-15, IL-12, IL-4, IL-5, IL-10; a chemokine; a growth factor; and the like.
[0107]
[0108] In some cases, a CAR of the present disclosure, when present in the plasma membrane of a eukaryotic cell and when activated by an antigen that binds to the antigen-binding domain of the CAR and a dimerizing agent, can result both an increase in the transcription of a nucleic acid in the cell and an increase in the production of a cytokine by the cell.
[0109]
[0110] In some cases, a CAR of the present disclosure, when present in the plasma membrane of a eukaryotic cell and when activated by a dimerizing agent, results in cytotoxic activity by the cell against a target cell that expresses on its surface an antigen to which the antigen binding domain of the first CAR polypeptide binds. For example, in cases where the eukaryotic cell is a cytotoxic cell (eg, an Nk cell or a cytotoxic T lymphocyte), a CAR of the present disclosure, when present in the plasma membrane of the cell and when activated by a dimerizing agent, increases the cytotoxic activity of the cell against a target cell that expresses on its surface an antigen to which the antigen binding domain of the first c A r polypeptide binds. For example, in cases where the eukaryotic cell is an NK cell or a cytotoxic T lymphocyte, a CAR of the present disclosure, when present on the plasma membrane of the cell and when activated by a dimerizing agent, increases activity. cell cytotoxic at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times or more than 10 times, compared to the cytotoxic activity of the cell in the absence of the dimerizing agent.
[0111]
[0112] In some cases, a CAR of the present disclosure, when present in the plasma membrane of a eukaryotic cell and when activated by an antigen that binds to the antigen-binding domain of the CAR and a dimerizing agent, can result other events related to CAR activation, such as proliferation and expansion (either due to increased cell division or anti-apoptotic responses).
[0113]
[0114] In some cases, a CAR of the present disclosure, when present in the plasma membrane of a eukaryotic cell and when activated by an antigen that binds to the antigen-binding domain of the CAR and a dimerizing agent, can result other events related to CAR activation, such as modulation of intracellular signaling, cell differentiation or cell death.
[0115]
[0116] A CAR of the present disclosure may be present on the membrane of a eukaryotic cell, where the first and second CAR polypeptides are not covalently linked to each other. A CAR of the present disclosure may be present on the membrane of a eukaryotic cell in the form of a single heterodimer that is not covalently bound to any other polypeptide on the membrane. Alternatively, a first CAR of the present disclosure may be present on the membrane of a eukaryotic cell in the form of a heterodimer that is covalently or non-covalently linked to a second CAR of the present disclosure. In some cases, the first and second CARs are covalently linked through a disulfide bond formed between the cysteines present in a hinge region present in both the first polypeptide of the first CAR and the first polypeptide of the second CAR.
[0117]
[0118] In some cases, a CAR of the present disclosure may be present on the membrane of a eukaryotic cell, where the first CAR polypeptides comprise an antibody fragment and the second CAR polypeptides comprise a signal transduction domain from a receptor of cytokines such that, after dimerization, the CAR may represent a heterodimeric signaling body CAR, eg, a signaling body consisting of at least two independent polypeptides. A "signaling body," as known in the art, is a single chimeric macromolecule consisting of an antibody fragment and a signal transduction domain from a cytokine receptor. In certain cases, a heterodimeric signaling body Ca R of the present disclosure, when present in the cell membrane of a eukaryotic cell, dimerized by a dimer and activated by an antigen, eg, an oligomerized antigen, can induce oligomerization of the heterodimeric signaling body CAR. Said ligand-induced oligomerization of a heterodimeric signaling body CAR can activate, for example, increase or perpetuate, for example, maintain, signal transduction, for example, ligand-induced oligomerization of a heterodimeric signaling body CAR can transmit a signal that triggers a cellular response. In some cases, a series of heterodimeric signaling body CARs can be employed in a combinatorial manner to trigger a desired cellular response.
[0119]
[0120] Member of a specific binding pair
[0121]
[0122] A CAR of the present disclosure includes a member of a specific binding pair. Specific binding pairs include, but are not limited to, antigen-antibody binding pairs; ligand-receptor binding pairs; and the like. Therefore, a member of a specific binding pair suitable for use in a CAR of the present disclosure includes an antigen; an antibody; a ligand; and a ligand binding receptor.
[0123]
[0124] Antigen binding domain
[0125]
[0126] A suitable antigen binding domain for use in a CAR of the present disclosure can be any antigen binding polypeptide, a wide variety of which are known in the art. In some cases, the antigen-binding domain is a single-chain Fv (scFv). Other antibody-based recognition domains (cAb VHH (camelid variable domains) and humanized versions, IgNAR VH (shark antibody variable domains) and humanized versions, sdAb VH (antibody variable domains) are suitable for use. single domain) and "camelized" antibody variable domains. In some cases, T-cell receptor-based recognition domains (TCRs) are also suitable for use, such as single-stranded TCRs (scTv, VaVp containing two domains). single-chain TCR).
[0127]
[0128] An antigen binding domain suitable for use in a CAR of the present disclosure can have various antigen binding specificities. In some cases, the antigen-binding domain is specific for an epitope present in an antigen that is expressed by (synthesized by) a cancer cell, that is, an antigen associated with cancer cells. The cancer cell associated antigen can be an antigen associated with, for example, a breast cancer cell, a B cell lymphoma, a Hodgkin lymphoma cell, an ovarian cancer cell, a prostate cancer cell, a mesothelioma, a lung cancer cell (for example, a small cell lung cancer cell), a B-cell non-Hodgkin lymphoma (B-NHL) cell, an ovarian cancer cell, a prostate cancer cell , a mesothelioma cell, a lung cancer cell (for example, a small cell lung cancer cell), a melanoma cell, a chronic lymphocytic leukemia cell, an acute lymphocytic leukemia cell, a neuroblastoma cell, a glioma, a glioblastoma, a medulloblastoma, a colorectal cancer cell, etc. An antigen associated with cancer cells can also be expressed by a non-cancer cell.
[0129]
[0130] Non-limiting examples of antigens to which the antigen binding domain of a specific CAR can bind include, for example, CD19, CD20, CD38, CD30, Her2 / neu, ERBB2, CA125, MUC-1, specific membrane antigen. prostate (PSMA), CD44 surface adhesion molecule, mesothelin, carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), EGFRvII, vascular endothelial growth factor receptor-2 (VEGFR2), antigen associated with melanoma of high molecular weight (HMW-MAA), MAGE-A1, IL-13R-a2, GD2 and the like.
[0131]
[0132] Flirting
[0133]
[0134] In some cases, a member of a specific binding pair suitable for use in a specific CAR is a ligand for a receptor. Ligands include, but are not limited to, cytokines (eg IL-13, etc.); growth factors (eg, herregulin; vascular endothelial growth factor (VEGf); and the like); an integrin-binding peptide (eg, a peptide comprising the Arg-Gly-Asp sequence); and the like.
[0135]
[0136] In cases where a member of a specific binding pair in a specific CAR is a ligand, the CAR can be activated in the presence of both a dimerizing agent and a second member of the specific binding pair, in this case being the second member of the specific binding pair a receptor for the ligand. For example, in cases where the ligand is VEGF, the second member of the specific binding pair may be a VEGF receptor, including a soluble VEGF receptor. As a further example, in cases where the ligand is herregulin, the second member of the specific binding pair may be Her2.
[0137]
[0138] Receivers
[0139]
[0140] As noted above, in some cases, the member of a specific binding pair that is included in a specific CAR is a receptor, for example, a receptor for a ligand, a co-receptor, etc. The receptor may be a ligand binding fragment of a receptor. Suitable receptors include, but are not limited to, a growth factor receptor (eg, a VEGF receptor); a cytolytic lymphocyte lectin-like receptor polypeptide, subfamily K, member 1 (NKG2D) (receptor for MICA, M iCb and ULB6); a cytokine receptor (eg, an IL-13 receptor; an IL-2 receptor; etc.); Her2; CD27; a natural cytotoxicity receptor (NCR) (eg, NKP30 (NCR3 / CD337) polypeptide (receptor for HLA-B-associated transcript 3 (BAT3) and B7-H6); etc.); etc.
[0141]
[0142] Hinge region
[0143]
[0144] In some cases, the first polypeptide of a particular CAR comprises a hinge region (also referred to herein as a "spacer"), the hinge region being found interposed between the antigen binding domain and the transmembrane domain. In some cases, the hinge region is an immunoglobulin heavy chain hinge region. In some cases, the hinge region is a hinge region polypeptide from a receptor (eg, a hinge region from CD8).
[0145]
[0146] The hinge region can be from about 4 amino acids to about 50 amino acids in length, for example, from about 4 aa to about 10 aa, from about 10 aa to about 15 aa, from about 15 aa to about 20 aa, from about 20 aa to approximately 25 aa, approximately 25 aa to approximately 30 aa, approximately 30 aa to approximately 40 aa or approximately 40 aa to approximately 50 aa.
[0147]
[0148] Suitable spacers can be easily selected and can be any of a number of suitable lengths, such as from 1 amino acid (eg Gly) to 20 amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to 12 amino acids, including from 4 amino acids to 10 amino acids, from 5 amino acids to 9 amino acids, from 6 amino acids to 8 amino acids or from 7 amino acids to 8 amino acids and can be 1,2, 3, 4, 5, 6 or 7 amino acids.
[0149] Exemplary spacers include glycine (G) n polymers, glycine-serine polymers (including, for example, (GS) n, (GSGGS) n (SEQ ID NO: 37), and (GGGS) n (SEQ ID NO: 38), where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers and other flexible linkers known in the art. Glycine and glycine-serine polymers can be used; Both Gly and Ser are relatively unstructured and can therefore serve as a neutral anchor between components. Glycine polymers can be used; glycine has access to a significantly larger phi-psi space even than alanine and is less restricted than residues with longer side chains (see Sheraga, Rev. Computational Chem. 11173-142 (1992)). Exemplary spacers can comprise amino acid sequences including, but not limited to, GGSG (SEQ ID NO: 39), GGSGG (SEQ ID NO: 40), GSGSG (SEQ ID NO: 41), GSGGG (SEQ ID NO : 42), GGGSG (SEQ ID NO: 43), GSSSG (SEQ ID NO: 44) and the like.
[0150]
[0151] In some cases, the hinge region in the first polypeptide of a particular CAR includes at least one cysteine. For example, in some cases, the hinge region may include the Cys-Pro-Pro-Cys sequence. If present, a cysteine in the hinge region of a first CAR may be available to form a disulfide bond with a hinge region in a second CAR.
[0152]
[0153] Amino acid sequences of immunoglobulin hinge regions are known in the art; see, for example, Tan et al. (1990) Proc. Natl. Acad. Sci. USA 87: 162; and Huck et al. (1986) Nucl. Acids Res. 14: 1779. By way of non-limiting examples, an immunoglobulin hinge region can include one of the following amino acid sequences: DKTHT (SEQ ID NO: 45); CPPC (SEQ ID NO: 46); CPEPKSCDTPPPCPR (SEQ ID NO: 47) (see, eg, Glaser et al. (2005) J. Biol. Chem. 280: 41494); ELKTPLGDTTHT (SEQ ID NO: 48); KSCDKTHTCP (SEQ ID NO: 49); KCCVDCP (SEQ ID NO: 50); KYGPPCP (SEQ ID NO: 51); EPKSCDKTHTCPPCP (SEQ ID NO: 52) (hinge for human IgG1); ERKCCVECPPCP (SEQ ID NO: 53) (human IgG2 hinge); ELKTPLGDTTHTCPRCP (SEQ ID NO: 54) (hinge for human IgG3); s Pn MVPHAHHa Q (SEQ ID NO: 55) (human IgG4 hinge); and the like.
[0154]
[0155] The hinge region may comprise an amino acid sequence of a hinge region of human IgG1, IgG2, IgG3, or IgG4. The hinge region may include one or more amino acid substitutions and / or insertions and / or deletions compared to a wild-type (naturally occurring) hinge region. For example, His229 of the human IgG1 hinge can be replaced by Tyr, such that the hinge region comprises the sequence EPKSCDKTYTCPPCP (SEQ ID NO: 52); see, for example, Yan et al. (2012) J. Biol. Chem. 287: 5891.
[0156]
[0157] The hinge region may comprise an amino acid sequence from human CD8; for example, the hinge region may comprise the amino acid sequence: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 56), or a variant thereof.
[0158] Transmembrane domain
[0159]
[0160] The first and second CAR polypeptides of the present disclosure include transmembrane domains for insertion into a eukaryotic cell membrane. The transmembrane domain of the first polypeptide is interposed between the antigen binding domain and the costimulatory domain. In cases where the first polypeptide includes a hinge region, the transmembrane domain is interposed between the hinge region and the costimulatory domain, such that the first polypeptide comprises, in order from amino terminus (N-terminus) to carboxyl terminus ( C-terminus): an antigen binding domain; a hinge region; a transmembrane domain; a first costimulatory domain; and a first member of a dimerizer binding pair.
[0161]
[0162] The transmembrane domain of the second polypeptide is at or near the N-terminus of the polypeptide, such that the second polypeptide comprises, in order from the N-terminus to the C-terminus: a transmembrane domain; a second costimulatory domain; a second member of the dimer binding pair; and an intracellular signaling domain.
[0163]
[0164] Any transmembrane (TM) domain that enables the insertion of a polypeptide into the cell membrane of a eukaryotic (eg, mammalian) cell is suitable for use. As a non-limiting example, the sequence TM, IYIWAPLAGTCGVLLLs Lv ITLYC (SEQ ID NO: 30) can be used. Additional non-limiting examples of Suitable TM sequences include: a) from CD8 beta: LGLLVAGVLVLLVSLGVAIHLCC (SEQ ID NO: 57); b) from CD4: ALIVLGGVAGLLLFIGLGIFFCVRC (SEQ ID NO: 58); c) from CD3 zeta: LCYLLDGILFIYGVILTALFLRV (SEQ ID NO: 59); d) from CD28: WVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 60); e) from CD134 (OX40): VAAILGLGLVLGLLGPLAILLALYLL (SEQ ID NO: 61); and f) from CD7: ALPAALAVISFLLGLGLGVACVLA (SEQ ID NO: 62).
[0165]
[0166] Linkers
[0167]
[0168] In some cases, a first polypeptide of a specific CAR includes a linker between any two adjacent domains. For example, a linker may be provided between the transmembrane domain and the first costimulatory domain of the first polypeptide. By way of further example, a linker may be provided between the first costimulatory domain and the first member of a dimerizer binding pair of the first polypeptide. As a further example, a linker may be provided between the transmembrane domain and the second costimulatory domain of the second polypeptide. By way of further example, a linker may be provided between the second costimulatory domain and the second member of a dimerizer binding pair of the second polypeptide. By way of further example, a linker may be provided between the second member of the dimerizer binding pair and the intracellular signaling domain of the second polypeptide.
[0169]
[0170] The linker peptide can have any of several amino acid sequences. Proteins can be linked by a spacer peptide, generally flexible in nature, although other chemical bonds are not excluded. A linker can be a peptide between about 6 and about 40 amino acids in length or between about 6 and about 25 amino acids in length. These linkers can be produced using synthetic oligonucleotides that encode the linkers to couple the proteins. Peptide linkers can be used with a certain degree of flexibility. Linker peptides can have virtually any amino acid sequence, keeping in mind that suitable linkers will have a sequence that results in a generally flexible peptide. The use of small amino acids, such as glycine and alanine, is useful in creating a flexible peptide. The creation of such sequences is routine for those skilled in the art.
[0171] Suitable linkers can be easily selected and can be any length that is suitable, such as from 1 amino acid (eg Gly) to 20 amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to 12 amino acids, including from 4 amino acids to 10 amino acids, from 5 amino acids to 9 amino acids, from 6 amino acids to 8 amino acids or from 7 amino acids to 8 amino acids and can be 1, 2, 3, 4, 5, 6 or 7 amino acids.
[0172] Exemplary peptide linkers include glycine (G) n polymers, glycine-serine polymers (including, for example, (GS) n, GSGGSn (Se Q ID NO: 37), and GGGSn (SEQ ID NO: 38) , where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers and other flexible linkers known in the art. Glycine and glycine-serine polymers are interesting since these two amino acids are relatively unstructured and therefore can serve as a neutral anchor between components. Glycine polymers are particularly interesting since glycine has access to a significantly larger phi-psi space even than alanine and is less restricted than residues with longer side chains (see Sheraga, Rev. Computational Chem. 11173-142 ( 1992)). Exemplary flexible linkers include, but are not limited to, GGSG (SEQ ID NO: 39), GGSGG (SEQ ID NO: 40), GSGSG (SEQ ID NO: 41), GSGGG (SEQ ID NO: 42), GGGSG (SEQ iD NO: 43), GSs Sg (SEQ ID NO: 44) and the like. One of ordinary skill in the art will recognize that the design of a peptide conjugated to any element described above can include linkers that are fully or partially flexible, such that the linker can include a flexible linker, as well as one or more portions that confer a less flexible structure.
[0173]
[0174] Modulating domains
[0175]
[0176] Modulator domains suitable for use in a CAR of the present disclosure include costimulatory domains.
[0177]
[0178] In some cases, the modulator domain of the first polypeptide of a particular CAR has substantially the same amino acid sequence as the modulator domain of the second CAR polypeptide. For example, in some cases, the modulator domain of the first polypeptide of a CAR comprises an amino acid sequence that is at least about 90%, at least about 95%, at least about 98%, at least about 99% or 100%, identical to the amino acid sequence of the modulator domain in the second CAR polypeptide. The modulator domain of the first polypeptide of a particular CAR can be substantially the same length as the modulator domain of the second polypeptide of a particular CAR; for example, the first and second modulator domains may differ from each other in length by less than 10 amino acids or less than 5 amino acids. In some cases, the first and second modulator domains can be the same length.
[0179] A modulator domain suitable for inclusion in the first and second polypeptides of a particular CAR may be from about 30 amino acids to about 70 amino acids (aa) in length, for example, a modulator domain may be from about 30 aa to about 35 aa, from approximately 35 aa to approximately 40 aa, from approximately 40 aa to approximately 45 aa, from approximately 45 aa to approximately 50 aa, approximately 50 aa to approximately 55 aa, approximately 55 aa to approximately 60 aa, approximately 60 aa to approximately 65 aa or approximately 65 aa to approximately 70 aa. In other cases, the modulator domain can be from about 70 aa to about 100 aa, from about 100 aa to about 200 aa, or more than 200 aa in length.
[0180]
[0181] Costimulatory domains suitable for use in a CAR of the present disclosure are generally receptor-derived polypeptides. In some embodiments, the costimulatory domains are homodimerized. A particular costimulatory domain may be an intracellular portion of a transmembrane protein (ie, the costimulatory domain may come from a transmembrane protein). Non-limiting examples of suitable costimulatory polypeptides include, but are not limited to, 4-1BB (CD137), CD28, ICOS, OX-40, BTLA, CD27, Cd 30, GITR, and HVEM.
[0182]
[0183] In some cases, the costimulatory domain of the first polypeptide of a particular CAR has substantially the same amino acid sequence as the costimulatory domain of the second CAR polypeptide. For example, in some cases, the costimulatory domain of the first polypeptide of a CAR comprises an amino acid sequence that is at least about 90%, at least about 95%, at least about 98%, at least about 99% or 100%, identical to the amino acid sequence of the costimulatory domain in the second CAR polypeptide. The costimulatory domain of the first polypeptide of a particular CAR may be substantially the same length as the costimulatory domain of the second polypeptide of a particular CAR; for example, the first and second costimulatory domains may differ from each other in length by less than 10 amino acids or less than 5 amino acids. In some cases, the first and second costimulatory domains can be the same length.
[0184]
[0185] A costimulatory domain suitable for inclusion in the first and second polypeptides of a particular CAR may be from about 30 amino acids to about 70 amino acids (aa) in length, for example, a costimulatory domain may be from about 30 aa to about 35 aa, approximately 35 aa to approximately 40 aa, approximately 40 aa to approximately 45 aa, approximately 45 aa to approximately 50 aa, approximately 50 aa to approximately 55 aa, approximately 55 aa to approximately 60 aa, approximately 60 aa to approximately 65 aa or approximately 65 aa to approximately 70 aa. In other cases, the costimulatory domain may be from about 70 aa to about 100 aa, from about 100 aa to about 200 aa, or more than 200 aa in length.
[0186]
[0187] In some cases, the costimulatory domain comes from an intracellular portion of the 4-1BB transmembrane protein (also known as TNFRSF9; CD137; 4-1BB; CDw137; ILA; etc.). For example, a suitable costimulatory domain may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at minus 98% or 100% amino acid sequence identity to the following amino acid sequence: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 24). In some of these embodiments, the costimulatory domain of both the first and second polypeptides is from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa at approximately 50 aa, from approximately 50 aa to approximately 55 aa, from approximately 55 aa to approximately 60 aa, from approximately 60 aa to approximately 65 aa or from approximately 65 aa to approximately 70 aa.
[0188]
[0189] In some cases, the costimulatory domain comes from an intracellular portion of the CD28 transmembrane protein (also known as Tp44). For example, a suitable costimulatory domain may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at minus 98% or 100% amino acid sequence identity to the following amino acid sequence: FWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO: 63). In some of these embodiments, the costimulatory domain of both the first and second polypeptides is from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa at approximately 50 aa, from approximately 50 aa to approximately 55 aa, from approximately 55 aa to approximately 60 aa, from approximately 60 aa to approximately 65 aa or from approximately 65 aa to approximately 70 aa.
[0190]
[0191] In some cases, the costimulatory domain comes from an intracellular portion of the ICOS transmembrane protein (also known as AILIM, CD278, and CVID1). For example, a suitable costimulatory domain may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at minus 98% or 100% amino acid sequence identity to the following amino acid sequence: TKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL (SEQ ID NO: 64). In some of these embodiments, the costimulatory domain of both the first and second polypeptides is from about 30 aa to about 35 aa, from about 35 aa to about 40 aa in length, from approximately 40 aa to approximately 45 aa, approximately 45 aa to approximately 50 aa, approximately 50 aa to approximately 55 aa, approximately 55 aa to approximately 60 aa, approximately 60 aa to approximately 65 aa or approximately 65 aa to approximately 70 aa.
[0192]
[0193] In some cases, the costimulatory domain comes from an intracellular portion of the OX-40 transmembrane protein (also known as TNFRSF4, RP5-902P8.3, ACT35, CD134, OX40, TXGP1L). For example, a suitable costimulatory domain may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at minus 98% or 100% amino acid sequence identity to the following amino acid sequence: RRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI (SEQ ID NO: 65). In some of these embodiments, the costimulatory domain of both the first and second polypeptides is from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa at approximately 50 aa, from approximately 50 aa to approximately 55 aa, from approximately 55 aa to approximately 60 aa, from approximately 60 aa to approximately 65 aa or from approximately 65 aa to approximately 70 aa.
[0194]
[0195] In some cases, the costimulatory domain comes from an intracellular portion of the BTLA transmembrane protein (also known as BTLA1 and CD272). For example, a suitable costimulatory domain may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at minus 98% or 100% amino acid sequence identity from the following amino acid sequence:
[0196]
[0197]
[0198]
[0199]
[0200] S (SEQ ID NO: 66).
[0201]
[0202] In some cases, the costimulatory domain comes from an intracellular portion of the CD27 transmembrane protein (also known as S152, T14, TNFRSF7, and Tp55). For example, a suitable costimulatory domain may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at minus 98% or 100% amino acid sequence identity to the following amino acid sequence: HQRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP (SEQ ID NO: 67). In some of these embodiments, the costimulatory domain of both the first and second polypeptides is from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa at approximately 50 aa, from approximately 50 aa to approximately 55 aa, from approximately 55 aa to approximately 60 aa, from approximately 60 aa to approximately 65 aa or from approximately 65 aa to approximately 70 aa.
[0203]
[0204] In some cases, the costimulatory domain comes from an intracellular portion of the CD30 transmembrane protein (also known as TNFRSF8, D1S166E, and Ki-1). For example, a suitable costimulatory domain may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at minus approximately 98% or 100% amino acid sequence identity with a contiguous series of approximately 100 amino acids to approximately 110 amino acids (aa), from approximately 110 aa to approximately 115 aa, from approximately 115 aa to approximately 120 aa, of approximately 120 aa to approximately 130 aa, approximately 130 aa to approximately 140 aa, approximately 140 aa to approximately 150 aa, approximately 150 aa to approximately 160 aa or approximately 160 aa to approximately 185 aa of the following amino acid sequence:
[0205]
[0206]
[0207]
[0208]
[0209]
[0210] EEEGKEDPLPTAASGK. (SEQ ID NO: 68).
[0211]
[0212] In some cases, the costimulatory domain comes from an intracellular portion of the GITR transmembrane protein (also known as TNFRSF18, RP5-902P8.2, AITR, c D357, and GITR-D). For example, a suitable costimulatory domain may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at minus 98% or 100% amino acid sequence identity to the following amino acid sequence: HIWQLRSQCMWPRETQLLLEVPPSTEDARSCQFPEEERGERSAEEKGRLGDLWV (SEQ ID NO: 69).
[0213] In some of these embodiments, the costimulatory domain of both the first and second polypeptides is from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa at approximately 50 aa, from approximately 50 aa to approximately 55 aa, from approximately 55 aa to approximately 60 aa, from approximately 60 aa to approximately 65 aa or from approximately 65 aa to approximately 70 aa.
[0214]
[0215] In some cases, the costimulatory domain comes from an intracellular portion of the HVEM transmembrane protein (also known as TNFRSF14, RP3-395M20.6, ATAR, CD270, HVEA, HVEM, LIGHTR, and TR2). For example, a suitable costimulatory domain may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at minus 98% or 100% amino acid sequence identity to the following amino acid sequence: CVKRRKPRGDVVKVIVSVQRKRQEAEGEATVIEALQAPPDVTTVAVEETIPSFTGRSPNH (SEQ ID NO: 70). In some of these embodiments, the costimulatory domain of both the first and second polypeptides is from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa at approximately 50 aa, from approximately 50 aa to approximately 55 aa, from approximately 55 aa to approximately 60 aa, from approximately 60 aa to approximately 65 aa or from approximately 65 aa to approximately 70 aa.
[0216]
[0217] Dimer pairs
[0218]
[0219] Dimer pairs suitable for use in a particular CAR include dimer binding pairs. The dimerizer binding pairs suitable for use in a CAR of the present disclosure are, in some embodiments, polypeptides that bind to a different site on the same molecule (referred to herein as "dimerizer"). In the presence of a dimerizer, both members of the dimerizer binding pair bind to a different site of the dimerizer and are therefore located close to each other. In some embodiments, binding to the dimer is reversible. In some embodiments, binding to the dimer is irreversible. In some embodiments, the binding to the dimerizer is non-covalent. In some embodiments, binding to the dimerizer is covalent.
[0220]
[0221] Other dimer pairs suitable for use include dimer binding pairs that dimerize upon binding of a first member of a pair of dimers to a dimerizing agent, the dimerizing agent inducing a conformational change in the first member of the pair of dimers. and allowing this conformational change for the first member of the pair of dimers to join (covalently or non-covalently) to a second member of the pair of dimers.
[0222] Other pairs of dimers suitable for use include pairs of dimers in which exposure to light (eg, blue light) induces dimerization of the pair of dimers.
[0223]
[0224] Regardless of the mechanism, the pair of dimers will dimerize upon exposure to an agent that induces dimerization, the agent being in some cases a small molecule or, in other cases, light. Therefore, for simplicity, the following description regarding "dimerizer binding pairs" includes pairs of dimers that dimerize regardless of mechanism.
[0225]
[0226] Non-limiting examples of suitable dimers (eg, dimer binding pairs) include, but are not limited to:
[0227]
[0228] a) FK506 binding protein (FKBP) and FKBP;
[0229] b) FKBP and the catalytic subunit A of calcineurin (CnA);
[0230] c) FKBP and cyclophilin;
[0231] d) FKBP and FKBP rapamycin-associated protein (FRB);
[0232] e) gyrase B (GyrB) and GyrB;
[0233] f) dihydrofolate reductase (DHFR) and DHFR;
[0234] g) DmrB and DmrB;
[0235] h) PYL and ABI;
[0236] i) Cry2 and CIB1; and
[0237] j) GAI and GID1.
[0238]
[0239] A first or second member of a dimer (eg, a dimer binding pair) of a particular CAR may be from about 50 amino acids to about 300 amino acids or more in length; for example, a first or a second member of a dimer (eg, a dimer binding pair) of a particular CAR may have a length of from about 50 aa to about 100 aa, from about 100 aa to about 150 aa, from approximately 150 aa to approximately 200 aa, from approximately 200 aa to approximately 250 aa, from approximately 250 aa to approximately 300 aa or more than 300 aa.
[0240]
[0241] In some cases, a member of a dimer (for example, a dimer binding pair) of a particular CAR comes from FKBP. For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least 98% or 100% amino acid sequence identity with respect to the following amino acid sequence:
[0242]
[0243]
[0244]
[0245]
[0246] ID NO: 12).
[0247]
[0248] In some cases, a member of a specific CAR dimerizer binding pair comes from the catalytic subunit A of calcineurin (also known as PPP3CA; CALN; CALNA; CALNA1; CCN1; CNA1; PPP2B; catalytic subunit CAM-PRP; calcineurin A alpha; calmodulin-dependent calcineurin A subunit alpha isoform; protein phosphatase 2B, catalytic subunit, alpha isoform; etc.). For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least 98% or 100% amino acid sequence identity with respect to the following amino acid sequence (PP2Ac domain):
[0249]
[0250]
[0251]
[0252]
[0253]
[0254]
[0255]
[0256] HPYWLPNFM (SEQ IDNO: 71).
[0257]
[0258] In some cases, a member of a dimer (eg, a dimer binding pair) is derived from cyclophilin (also known as cyclophilin A, PPIA, CYPa, CYPH, PPIase A, etc.). For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least 98% or 100% amino acid sequence identity with respect to the following amino acid sequence:
[0259]
[0260]
[0261]
[0262]
[0263]
[0264] ID NO; 72).
[0265]
[0266] In some cases, a member of a dimer (eg, a dimerizer binding pair) comes from MTOR (also known as rapamycin-associated protein-FKBP; FK506-binding protein 12-rapamycin-associated protein 1; binding protein a FK506 12-rapamycin-associated protein 2; FK506 12-binding protein-associated rapamycin complex 1; FRAP; FRAP1; FRAP2; RAFT1; and RAPT1). For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least 98% or 100% amino acid sequence identity to the following amino acid sequence (also known as "Frb": Fkbp-rapamycin-binding domain):
[0267]
[0268]
[0269]
[0270]
[0271] In some cases, a member of a dimer (eg, a dimerizer binding pair) comes from GyrB (also known as the DNA gyrase B subunit). For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least approximately 98% or 100% amino acid sequence identity with a contiguous series of approximately 100 amino acids to approximately 200 amino acids (aa), from approximately 200 aa to approximately 300 aa, approximately 300 aa to approximately 400 aa, approximately 400 aa to approximately 500 aa, approximately 500 aa to approximately 600 aa, approximately 600 aa to approximately 700 aa or approximately 700 aa to approximately 800 aa, from the following GyrB amino acid sequence of Escherichia coli (or with the DNA gyrase subunit B sequence of any organism):
[0272] MSNSYDSSSIKVLKGLDAVRKRPGMYIGDTDDGTGLHHMVFEVVDNAIDEALAGH CKEIIVTIHADNSVSVQDDGRGIPTGIHPEEGVSAAEVIMTVLHAGGKFDDNSYKVS GGLHGVGVSVVNALSQKLELVIQREGKIHRQIYEHGVPQAPLAVTGETEKTGTMV RFWPSLETFTNVTEFEYEILAKRLRELSFLNSGVSIRLRDKRDGKEDHFHYEGGIKAF VEYLNKNKTPIHPNIFYFSTEKDGIGVEVALQWNDGFQENIYCFTNNIPQRDGGTHL AGFRAAMTRTLNAYMDKEGYSKKAKVSATGDDAREGLIAVVSVKVPDPKFSSQT KDKLVSSEVKSAVEQQMNELLAEYLLENPTDAKIVVGKIIDAARAREAARRAREM TRRKGALDLAGLPGKLADCQERDPALSELYLVEGDSAGGSAKQGRNRKNQAILPL KGKILNVEKARFDKMLSSQEVATLITALGCGIGRDEYNPDKLRYHSIIIMTDADVDG SHIRTLLLTFFYRQMPEIVERGHVYIAQPPLYKVKKGKQEQYIKDDEAMDQYQISIA LDGATLHTNASAPALAGEALEKLVSEYNATQKMINRMERRYPKAMLKELIYQPTL TEADLSDEQTVTRWVNALVSELNDKEQHGSQWKFDVHTNAEQNLFEPIVRVRTHG VDTDYPLDHEFITGGEYRRICTLGEKLRGLLEEDAFIERGERRQPVASFEQALDWLV KESRRGLSIQRYKGLGEMNPEQLWETTMDPESRRMLRVTVKDAIAADQLFTTLMG DAVEPRRAFIEENALKAANIDI
[0273] (SEQ ID NO: 73). In some cases, a member of a dimerizer binding pair comprises an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least 98% or 100% amino acid sequence identity with respect to amino acids 1-220 of the aforementioned GyrB amino acid sequence of Escherichia coli.
[0274]
[0275] In some cases, a member of a dimer (eg, a dimerizer binding pair) comes from DHFR (also known as dihydrofolate reductase, DHFRP1, and DYR). For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least 98% or 100% amino acid sequence identity with respect to the following amino acid sequence:
[0276]
[0277]
[0278]
[0279]
[0280]
[0281] DVQEEKGIKYKFEVYEKND (SEQ ID NO: 74).
[0282]
[0283] In some cases, a member of a dimer (eg, a dimer binding pair) comes from the DmrB binding domain (ie, the DmrB homodimerization domain). For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least 98% or 100% amino acid sequence identity with respect to the following amino acid sequence:
[0284]
[0285]
[0286]
[0287]
[0288] (SEQ ID NO: 75).
[0289]
[0290] In some cases, a member of a dimer (eg, a dimerizer binding pair) comes from a PYL protein (also known as abscisic acid receptor and RCAR). For example, a member of a particular dimerizer binding pair can come from proteins such as those from Arabidopsis thaliana: PYR1, RCAR1 (PYL9), PYL1, PYL2, PYL3, PYL4, PYL5, PYL6, PYL7, PYL8 (RCAR3), PYL10, PYL11, PYL12, PYL13. For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or 100% amino acid sequence identity with any of the following amino acid sequences:
[0291]
[0292] PYL10:
[0293] RLQAESMEKK1 (SEQ ID NO: 76).
[0294]
[0295] PYL11:
[0296]
[0297] NO: 77)
[0298]
[0299] PYL12:
[0300]
[0301] MKTSQEQHVCGSTVVQTINAPLPLVWSILRRFDNPKTFKHFVKTCKLRSGDGGEGS VREVTVVSDLPASFSLERLDELDDESHVMVISIIGGDHRLVNYQSKTTVFVAAEEEK
[0302] NO: 78).
[0303]
[0304] PYL13:
[0305]
[0306]
[0307] EGKGSVRDVTLVSGFPADFSTERLEELDDESHVMVVSIIGGNHRLVNYKSKTKVVA
[0308] ID NO: 79).
[0309]
[0310] PYL1:
[0311]
[0312]
[0313] NO: 80).
[0314]
[0315] PYL2:
[0316]
[0317] GGEHRLKNYKSVTSVNEFLNQDSGKVYTVVLESYTVDIPEGNTEEDTKMFVDTVV KLNLQKLGVAATSAPMHDDE (SEQ ID NO: 81).
[0318]
[0319] PYL3:
[0320] IPQGNTEEDTRMFVDTVVKSNLQNLAVISTASPT (SEQ ID NO: 82).
[0321]
[0322] PYL4:
[0323]
[0324]
[0325] KEETCDFVDVIVRCNLQSLAKJAENTAAESKKKMSL (SEQ ID NO: 83).
[0326]
[0327] PYL5:
[0328]
[0329]
[0330] ESYIVDVPPGNTEEETLSFVDTIVRCNLQSLARSTNRQ (SEQ ID NO: 84).
[0331]
[0332] PYL6:
[0333]
[0334] MPTSIQFQRSSTAAEAANATVRNYPHHHQKQVQKVSLTRGMADVPEHVELSHTHV VGPSQCFSVVVQDVEAPVSTVWSILSRFEHPQAYKHFVKSCHEVGVVDGVDGVDGVVDGVDHVGVDHVDGV
[0335] NO: 85).
[0336]
[0337] PYL7:
[0338]
[0339]
[0340] VRRFDQPQKYKPFISRCTVNGDPEIGCLREVNVKSGLPATTSTERLEQLDDEEHILGI NIIGGDHRLKNYSSILTVHPEMIDGRSGTMVMESFVVDVPQGNTKDDTCYFVESLIK
[0341]
[0342] PYL8:
[0343]
[0344]
[0345] PQKYKPFISRCVVKGNMEIGTVREVDVKSGLPATRSTERLELLDDNEHILSIRIVGGD HRLKNYSSHSLHPET1EGR1GTLV1ESFVVDVPEGNTKDETCYFVEAL1KCNLKSLAD ISERLAVQDTTESRV: 87
[0346]
[0347] PYL9:
[0348] KSLADVSERLASQDITQ (SEQ ID NO: 88).
[0349]
[0350] PYR1:
[0351]
[0352] ATVAEAMARNSGDGSGSQVT (SEQ ID NO: 89).
[0353]
[0354] In some cases, a member of a dimer (eg, a dimer binding pair) comes from an ABI protein (also known as abscisic acid insensitive). For example, a member of a particular dimerizer binding pair may come from proteins such as those from Arabidopsis thaliana: ABI1 (also known as ABSCISIC ACID INSENSITIVE 1, Protein phosphatase 2C 56, AtPP2C56, P2C56 and PP2C ABI1) and / or ABI2 (also known as P2C77, Protein phosphatase 2C 77, AtPP2C77, INSENSITIVE TO ABSCISIC ACID 2, Protein phosphatase 2C ABI2 and PP2C ABI2). For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least approximately 98% or 100% amino acid sequence identity with a contiguous series of approximately 100 amino acids to approximately 110 amino acids (aa), from approximately 110 aa to approximately 115 aa, from approximately 115 aa at approximately 120 aa, from approximately 120 aa to approximately 130 aa, from approximately 130 aa to approximately 140 aa, from approximately 140 aa to approximately 150 aa, from approximately 150 aa to approximately 160 aa, from approximately 160 aa to approximately 170 aa, from approximately 170 aa to approximately 180 aa, from approximately 180 aa to approximately 190 aa or from approximately 190 aa to approximately 200 aa of any of the following amino acid sequences:
[0355] ABI1:
[0356] MEEVSPAIAGPFRPFSETQMDFTGIRLGKGYCNNQYSNQDSENGDLMVSLPETSSCS
[0357] GVYDGHGGSQVANYCRERMHLALAEEIAKEKPMLCDGDTWLEKWKKALFNSFLR VDSEIESVAPETVGSTSVVAVVFPSHIFVANCGDSRAVLCRGKTALPLSVDHKPDRE
[0358] CLILASDGVWDVMTDEEACEMARKRILLWHKKNAVAGDASLLADERRKEGKDPA
[0359]
[0360] ABI2:
[0361] QVANYCRERMHLALTEEIVKEKPEFCDGDTWQEKWKKALFNSFMRVDSEIETVAH
[0362] GLWDVMTNEEVCDLARKRILLWHKKNAMAGEALLPAEKRGEGKDPAAMSAAEY LSKM ALQKGSKDNISVVVVDLKGIRKFKSKSLN (SEQ ID N0: 91).
[0363]
[0364] In some cases, a member of a dimer (eg, a dimerizer binding pair) comes from a Cry2 protein (also known as cryptochrome 2). For example, a member of a particular dimer (eg, a dimer binding pair) can come from Cry2 proteins from any organism (eg, a plant) such as, but not limited to, those from Arabidopsis thaliana. For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least approximately 98% or 100% amino acid sequence identity with a contiguous series of approximately 100 amino acids to approximately 110 amino acids (aa), from approximately 110 aa to approximately 115 aa, from approximately 115 aa at approximately 120 aa, from approximately 120 aa to approximately 130 aa, from approximately 130 aa to approximately 140 aa, from approximately 140 aa to approximately 150 aa, from approximately 150 aa to approximately 160 aa, from approximately 160 aa to approximately 170 aa, from approximately 170 aa to approximately 180 aa, from approximately 180 aa to approximately 190 aa or from approximately 190 aa to approximately 200 aa of any of the following Amino acid sequences:
[0365] Cry2 (Arabidopsis thaliana)
[0366]
[0367] NO: 92).
[0368]
[0369] In some cases, a member of a dimer (eg, a dimerizer binding pair) is derived from the Arabidopsis thaliana protein CIB1 (also known as transcription factor bHLH63). For example, a suitable dimer (eg, a member of a dimerizer binding pair) can comprise an amino acid sequence that is at least 75%, at least about 80%, at least about 85%, at least approximately 90%, at least approximately 95%, at least approximately 98% or 100% amino acid sequence identity with a contiguous series of approximately 100 amino acids to approximately 110 amino acids (aa), from approximately 110 aa to approximately 115 aa, from approximately 115 aa to approximately 120 aa, from approximately 120 aa to approximately 130 aa, from approximately 130 aa to approximately 140 aa, from approximately 140 aa to approximately 150 aa, from approximately 150 aa to approximately 160 aa, from approximately 160 aa to approximately 170 aa, from approximately 170 aa to approximately 180 aa, from approximately 180 aa to approximately 190 aa or from about 190 aa to about 200 aa of the following amino acid sequence:
[0370]
[0371]
[0372]
[0373]
[0374]
[0375]
[0376]
[0377]
[0378] V (SEQ ID NO: 93).
[0379]
[0380] In some cases, a member of a dimer (eg, a dimerizer binding pair) is derived from the Arabidopsis thaliana GAI protein (also known as insensitive to gibberellic acid and GAI DELLA protein). For example, a member of a suitable dimer binding pair may comprise an amino acid sequence having at least 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least approximately amino acid sequence identity with a contiguous series of approximately approximately 110 amino acids (aa), from approximately 110 aa to appro approximately 115 aa to approximately 120 aa, from approximately 120 to 130 aa, from approximately 130 aa to approximately 140 aa, from approximately 140 to 150 aa, from approximately 150 aa to approximately 160 aa, from approximately 160
[0381]
[0382]
[0383]
[0384]
[0385]
[0386]
[0387]
[0388]
[0389]
[0390]
[0391]
[0392]
[0393] EGYRVEESDGCLMLGWHTRPLIATSAWKLSTN (SEQ ID NO: 94).
[0394]
[0395] In some cases, a member of a dimer (eg, a dimerizer binding pair) is derived from a GID1 protein from Arabidopsis thaliana (also known as a gidrelin GID1 receptor). For example, a suitable dimer member can comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% , at least about 98% or 100% amino acid sequence identity with a contiguous series of about 100 amino acids to about 110 amino acids (aa), from about 110 aa to about 115 aa, from about 115 aa to about 120 aa , from approximately 120 aa to approximately 130 aa, from approximately 130 aa to approximately 140 aa, from approximately 140 aa to approximately 150 aa, from approximately 150 aa to approximately 160 aa, from approximately 160 aa to approximately 170 aa, from approximately 170 aa to approximately 180 aa, approximately 180 aa to approximately 190 aa or approximately 190 aa to approximately 200 aa of any of the following Before amino acid sequences:
[0396]
[0397] GID1A:
[0398]
[0399]
[0400]
[0401]
[0402]
[0403]
[0404] DEISAFVNAEC (SEQ ID NO: 95).
[0405]
[0406] GID1B:
[0407]
[0408]
[0409]
[0410]
[0411]
[0412]
[0413]
[0414]
[0415] MEELNKFVHSIEDSQSKSSPVLLTP (SEQ ID NO: 96)
[0416]
[0417] GID1C:
[0418]
[0419] MAGSEEVNLIESKTVVPLNTWVLISNFKLAYNLLRRPDGTFNRHLAEFLDRKVPAN
[0420] ANPVNGVFSFDVIIDRQTNLLSRVYRPADAGTSPSITDLQNPVDGEIVPVIVFFHGGS
[0421]
[0422]
[0423]
[0424]
[0425]
[0426] AFVNAECQ (SEQ ID NO: 97).
[0427]
[0428] Dimmers
[0429]
[0430] Dimerizers ("dimerizing agents") that can enable dimerization of a first member of a dimerizer-binding pair and a second member of a dimerizer-binding pair include, for example (the dimerizer being in parentheses following the pair dimer binding):
[0431]
[0432] a) FKBP and FKBP (rapamycin);
[0433] b) FKBP and CnA (rapamycin);
[0434] c) FKBP and cyclophilin (rapamycin);
[0435] d) FKBP and FRG (rapamycin);
[0436] e) GyrB and GyrB (coumermycin);
[0437] f) DHFR and DHFR (methotrexate);
[0438] g) DmrB and DmrB (AP20187);
[0439] h) PYL and ABI (abscisic acid);
[0440] i) Cry2 and CIB1 (blue light); and
[0441] j) g A i and GID1 (gibberellin).
[0442] As stated above, rapamycin can serve as a dimer. Alternatively, a derivative or analog of rapamycin can be used. See, eg, WO96 / 41865; WO 99/36553; WO 01/14387; and Ye et al. (1999) Science 283: 88-91. For example, rapamycin structurally related analogs, homologs, derivatives and other compounds ("rapalogs") include, but are not limited to, rapamycin variants that have one or more of the following modifications relative to rapamycin: demethylation, deletion, or methoxy replacement at C7, C42 and / or C29; removal, derivatization or replacement of hydroxy at C13, C43 and / or C28; reduction, elimination or derivatization of the ketone at C14, C24 and / or C30; replacement of the 6-membered pipecholate ring with a 5-membered prolyl ring; an alternative substitution on the cyclohexyl ring or replacement of the cyclohexyl ring by a substituted cyclopentyl ring. Additional information has been presented in, for example, US Patent Nos. 5,525,610; 5,310,903 5,362,718; and 5,527,907. Selective epimerization of the C-28 hydroxyl group has been described; see, eg, WO 01/14387. Additional synthetic dimerizing agents suitable for use as an alternative to rapamycin include those described in United States Patent Publication No. 2012/0130076.
[0443]
[0444] Rapamycin has the structure:
[0445]
[0446]
[0447]
[0448]
[0449] Suitable rapalogs include, for example,
[0450]
[0451]
[0452]
[0453]
[0454] Also useful as a rapture is a compound of the formula:
[0455]
[0456]
[0457] where n is 1 or 2; R28 and R43 are independently H or a substituted or unsubstituted aliphatic or acyl residue; one of R7a and R7b is H and the other is halo, RA, ORA, SRA, -OC (O) RA, -OC (O) NRARB, -NRARB, -NRBC (OR) RA, NRBC (O) ORA, - NRbSO2Ra on RbSO2NRaRb '; or R7a and R7b, taken together, are H in the tetraene moiety:
[0458]
[0459]
[0460]
[0461]
[0462] where RA is H or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety and where RB and RB 'are independently H, OH or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl or heteroaryl moiety.
[0463]
[0464] As previously stated, coumermycin can serve as a dimerizing agent. Alternatively, a coumermycin analog can be used. See, for example, Farrar et al. (1996) Nature 383: 178-181; and United States Patent No. 6,916,846.
[0465]
[0466] As noted above, in some cases, the dimerizing agent is methotrexate, eg, a non-cytotoxic homobifunctional methotrexate dimer. See, for example, United States Patent No. 8,236,925.
[0467] Intracellular signaling domain
[0468]
[0469] Intracellular signaling domains suitable for use in a CAR of the present disclosure include any desired signaling domain that provides a distinct and detectable signal (eg, increased production of one or more cytokines by the cell; change in transcription of a target gene; change in the activity of a protein; change in cell behavior, e.g., cell death; cell proliferation; cell differentiation; cell survival; modulation of cell signaling responses; etc.) in response to activation of the CAR (that is, activated by an antigen and a dimerizing agent). In some embodiments, the intracellular signaling domain includes at least one (eg, one, two, three, four, five, six, etc.) ITAM motifs as described below. In some embodiments, the intracellular signaling domain includes DAP10 / CD28 type signaling chains. In some embodiments, the intracellular signaling domain is non-covalently bound to the membrane bound CAR, but instead diffuses into the cytoplasm.
[0470]
[0471] ITAM
[0472]
[0473] Intracellular signaling domains suitable for use in a CAR of the present disclosure include intracellular signaling polypeptides containing a tyrosine-based immunoreceptor (ITAM) activation motif. An ITAM motif is YX1X2L / I, where X1 and X2 are independently any amino acid (SEQ ID NO: 130). In some cases, the intracellular signaling domain of a particular CAR comprises 1, 2, 3, 4, or 5 ITAM motifs. In some cases, in an intracellular signaling domain, an ITAM motif is repeated twice, the first and second occurrences of the ITAM motif being separated by 6 to 8 amino acids, for example, (YX1X2L / IXX3MYX1X2L / I), where n is an integer from 6 to 8 and each of the 6-8 X3s can be any amino acid (SEQ ID NO: 131). In some cases, the intracellular signaling domain of a particular CAR comprises 3 ITAM motifs.
[0474]
[0475] A suitable intracellular signaling domain can be a portion containing an ITAM motif that comes from a polypeptide containing an ITAM motif. For example, a suitable intracellular signaling domain can be a domain that contains an ITAM motif from a protein that contains any ITAM motif. Therefore, a suitable intracellular signaling domain need not contain the complete sequence of the complete protein from which it is derived. Examples of polypeptides containing suitable ITAM motifs include, but are not limited to: DAP12; FCER1G (Fc epsilon receptor gamma I chain); CD3D (CD3 delta); CD3E (Cd 3 epsilon); CD3G (CD3 gamma); CD3Z (CD3 zeta); and CD79A (alpha chain of protein associated with antigen receptor complex).
[0476]
[0477] In some cases, the intracellular signaling domain comes from DAP12 (also known as TYROBP; tyrosine kinase protein binding protein TYRO; KARAP; PLOSL; DNAX 12 activation protein; KAR-associated protein; protein tyrosine kinase binding protein TYRO; elimination activation receptor-associated protein; elimination activation receptor-associated protein; etc.). For example, a suitable intracellular signaling domain polypeptide may comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least approximately 98% or 100%, of amino acid sequence identity with respect to any of the following amino acid sequences (4 isoforms):
[0478]
[0479] MGGLEPCSRLLLLPLLLAVSGLRPVQAQAQSDCSCSTVSPGVLAGIVMGDLVLTVLI
[0480]
[0481]
[0482] K (SEQ ID NO: 98);
[0483]
[0484] MGGLEPCSRLLLLPLLLAVSGLRPVQAQAQSDCSCSTVSPGVLAGIVMGDLVLTVLI
[0485]
[0486]
[0487] (SEQ ID NO: 99);
[0488]
[0489]
[0490]
[0491]
[0492] NO: 100); or
[0493]
[0494]
[0495]
[0496]
[0497] where ITAM motifs are in bold and underlined.
[0498]
[0499] Similarly, a suitable intracellular signaling domain polypeptide can comprise a portion containing an ITAM motif from the full length DAP12 amino acid sequence. Therefore, a suitable intracellular signaling domain polypeptide can comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or 100%, amino acid sequence identity to the following amino acid sequence: ESPYQELQGQRSDVYSDLNTQ (SEQ ID NO: 102), where ITAM motifs are in bold and underlined.
[0500] In some cases, the intracellular signaling domain comes from FCER1G (also known as FCRG; Fc epsilon receptor gamma chain I; Fc receptor gamma chain; Fc-epsilon RI-gamma; FcRgamma; FceRI gamma; gamma subunit receptor epsilon high affinity immunoglobulin; immunoglobulin E receptor, high affinity, gamma chain; etc.). For example, a suitable intracellular signaling domain polypeptide may comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least 98% or 100% amino acid sequence identity with respect to the following amino acid sequence: MIPAVVLLLLLLVEQAAALGEPQLCYILDAILFLYGIVLTLLYCRLKIQVRKAAITSYEKSDGVYTGLSTRNQ where the SEQUs are found, (QQQQE), (Q) are found (IDs), SEQIs, QQQQEs, QIQs, QQQQEs, (Q) are found (IDs), which are:
[0501] Similarly, a suitable intracellular signaling domain polypeptide can comprise a portion containing an ITAM motif from the full length FCER1G amino acid sequence. Therefore, a suitable intracellular signaling domain polypeptide can comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least approximately 98% or 100%, of amino acid sequence identity to the following amino acid sequence: DGVYTGLSTRNOETYETLKHE (SEQ ID NO: 104), where ITAM motifs are in bold and underlined.
[0502] In some cases, the intracellular signaling domain comes from the delta chain of the glycoprotein on the surface of CD3 T lymphocytes (also known as c D3D; CD3-DELTA; T3D; CD3 antigen, delta subunit; c D3 delta; CD3d antigen , delta polypeptide (TiT3 complex); OKT3, delta chain; T lymphocyte T3 receptor delta chain; CD3 T cell surface glycoprotein delta chain; etc.). For example, a suitable intracellular signaling domain polypeptide may comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or 100%, amino acid sequence identity with a contiguous series of about 100 amino acids to about 110 amino acids (aa), from about 110 aa to about 115 aa, from about 115 aa to approximately 120 aa, approximately 120 aa to approximately 130 aa, approximately 130 aa to approximately 140 aa, approximately 140 aa to approximately 150 aa or approximately 150 aa to approximately 170 aa, of any of the following amino acid sequences ( 2 isoforms):
[0503]
[0504]
[0505]
[0506]
[0507]
[0508] N K (SEQ ID NO: 105) or
[0509] MEHSTFLSGLVLATLLSQVSPFKIPIEELEDRVFVNCNTSITWVEGTVGTLLSDITRL DLGKRILDPRGIYRCNGTDIYKDKESTVOVHYRTAPTOALLRNDOVYQPLRDRDD AQYSHLGGNWARNK () SEQ IDs where: NOQs:)
[0510]
[0511] Similarly, a suitable intracellular signaling domain polypeptide can comprise a portion containing an ITAM motif from the full length CD3 delta amino acid sequence. Therefore, a suitable intracellular signaling domain polypeptide can comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or 100%, amino acid sequence identity to the following amino acid sequence: DQVYQPLRDRDDAQYSHLGGN (SEQ ID NO: 107), where ITAM motifs are in bold and underlined.
[0512] In some cases, the intracellular signaling domain comes from the epsilon chain of glycoprotein on the surface of CD3 T lymphocytes (also known as CD3e, epsilon chain of T3 / Leu-4 antigen on T cell surface, epsilon chain of the glycoprotein of the surface of T lymphocytes CD3, AI504783, CD3, CD3epsilon, T3e, etc.). For example, a suitable intracellular signaling domain polypeptide may comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or 100%, amino acid sequence identity with a contiguous series of about 100 amino acids to about 110 amino acids (aa), from about 110 aa to about 115 aa, from about 115 aa to approximately 120 aa, approximately 120 aa to approximately 130 aa, approximately 130 aa to approximately 140 aa, approximately 140 aa to approximately 150 aa or approximately 150 aa to approximately 205 aa, of the following amino acid sequence:
[0513] MQSGTHWRVLGLCLLSVGVWGQDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGS DEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDVMSVATIVIVDICITGGLLLLVYYWSKNR KAKAKPVTRGAG AGGRORGONKERPPPVPNPDYEPIRKGORDLYSGLNORRI (SEQ ID NO: 108), where the ITAM motifs are in bold and underlined.
[0514]
[0515] Similarly, a suitable intracellular signaling domain polypeptide may comprise a portion containing an iTa M motif from the full length CD3 epsilon amino acid sequence. Therefore, a suitable intracellular signaling domain polypeptide can comprise an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or 100%, of amino acid sequence identity to the following amino acid sequence: NPDYEPIRKGQRDLYSGLNQR (SEQ ID NO: 109), where ITAM motives are in bold and underlined.
[0516]
[0517] In some cases, the intracellular signaling domain comes from the gamma chain of the glycoprotein on the surface of CD3 T lymphocytes (also known as c D3G, gamma chain of T3 receptor T lymphocytes, CD3-GAMMA, T3G, gamma polypeptide ( TiT3 complex, etc.). For example, a suitable intracellular signaling domain polypeptide may comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or 100%, amino acid sequence identity with a contiguous series of about 100 amino acids to about 110 amino acids (aa), from about 110 aa to about 115 aa, from about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 180 aa, of the following amino acid sequence: MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAK DPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLFAEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPND QLY QPLKDRE DDQYSHLQGNQLRRN (SEQ ID NO: 110), where ITAM reasons are in bold and underlined.
[0518]
[0519] Similarly, a suitable intracellular signaling domain polypeptide can comprise a portion containing an iTa M motif from the full-length CD3 gamma amino acid sequence. Therefore, a suitable intracellular signaling domain polypeptide can comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or 100%, amino acid sequence identity to the following amino acid sequence: DQLYQPLKDREDDOYSHLQGN (SEQ ID NO: 111), where ITAM motifs are in bold and underlined.
[0520]
[0521] In some cases, the intracellular signaling domain comes from the zeta chain of the glycoprotein on the surface of CD3 T lymphocytes (also known as CD3Z, T3 T cell receptor zeta chain, CD247, CD3-ZETA, CD3H, CD3Q, T3Z, TCRZ, etc.). For example, a suitable intracellular signaling domain polypeptide may comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or 100%, amino acid sequence identity with a contiguous series of about 100 amino acids to about 110 amino acids (aa), from about 110 aa to about 115 aa, from about 115 aa to approximately 120 aa, approximately 120 aa to approximately 130 aa, approximately 130 aa to approximately 140 aa, approximately 140 aa to approximately 150 aa or approximately 150 aa to approximately 160 aa, of any of the following amino acid sequences ( 2 isoforms):
[0522]
[0523]
[0524]
[0525]
[0526]
[0527] (SEQ ID NO: l 12) or
[0528] MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRS ADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLY NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 113), where the ITAM motifs are in bold and underlined.
[0529]
[0530] Similarly, a suitable intracellular signaling domain polypeptide can comprise a portion containing an ITAM motif from the full length CD3 zeta amino acid sequence. Therefore, a suitable intracellular signaling domain polypeptide can comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least approximately 98% or 100%, of amino acid sequence identity with respect to any of the following amino acid sequences:
[0531]
[0532]
[0533] ALPPR (SEQ ID NO: 18);
[0534]
[0535] NQLYNELNLGRREEYDVLDKR (SEQ ID NO: 114);
[0536] EGLYNELQKDKMAEAYSEIGMK (SEQ ID NO: 115); or
[0537] DGLYQGLSTATKDTYDALHMQ (Se Q ID NO: 116), where ITAM motifs are in bold and underlined.
[0538] In some cases, the intracellular signaling domain comes from CD79A (also known as the alpha chain of protein associated with the B cell antigen receptor complex; CD79a antigen (alpha associated with immunoglobulins); membrane glycoprotein MB-1; Ig-alpha ; membrane-bound immunoglobulin-associated protein; IgM-associated surface protein; etc.). For example, a suitable intracellular signaling domain polypeptide may comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or 100%, amino acid sequence identity with a contiguous series of about 100 amino acids to about 110 amino acids (aa), from about 110 aa to about 115 aa, from about 115 aa to approximately 120 aa, approximately 120 aa to approximately 130 aa, approximately 130 aa to approximately 150 aa, approximately 150 aa to approximately 200 aa or approximately 200 aa to approximately 220 aa, of any of the following amino acid sequences ( 2 isoforms):
[0539]
[0540] MPGGPGVLQALPATIFLLFLLSAVYLGPGCQALWMHKVPASLMVSLGEDA
[0541]
[0542]
[0543]
[0544]
[0545] IGDVQLEKP (SEQ ID NO: 117); or
[0546] MPGGPGVLQALPATIFLLFLLSAVYLGPGCQALWMHKVPASLMVSLGEDAHFQCPHNSSNNANVTWWRVLHGNYT WPPEFLGPGEDPNEPPPRPFLDMGEGTKNRMTAEGMLLFCAVVPGTLLLFRKRWQNEKLGLDAGDEYEDENLYEGL NLDDCSMYE DISRGLQGTYQDVGSLNIGDVQLEKP (SEQ ID NO: 118), where the ITAM motifs are in bold and underlined.
[0547]
[0548] Similarly, a suitable intracellular signaling domain polypeptide can comprise a portion containing an ITAM motif from the full-length CD79A amino acid sequence. Therefore, a suitable intracellular signaling domain polypeptide can comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least approximately 95%, at least approximately 98% or 100%, of amino acid sequence identity to the following amino acid sequence: ENLYEGLNLDDCSMYEDISRG (SEQ ID NO: 119), where ITAM motifs are in bold and underlined.
[0549]
[0550] DAP10 / CD28
[0551]
[0552] Intracellular signaling domains suitable for use in a CAR of the present disclosure include a signaling chain of the DAP10 / CD28 type.
[0553]
[0554] An example of a DAP10 signaling chain is the amino acid sequence: RPRRSPAQDGKVYINMPGRG (SEQ ID NO: 120). In some embodiments, an intracellular signaling domain comprises an amino acid sequence having at least 85%, at least about 90%, at least about 95%, at least 98%, or at least 99%, identity of amino acid sequence to full length amino acid sequence RPRRSPAQDGKVYINMPGRG (SEQ ID NO: 120).
[0555]
[0556] An example of a CD28 signaling chain is the amino acid sequence FWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO: 121). In some embodiments, an intracellular signaling domain comprises an amino acid sequence having at least 85%, at least about 90%, at least about 95%, at least 98%, or at least 99%, identity amino acid sequence to full length amino acid sequence
[0557] PYAPPRDFAAYRS (SEQ ID NO: 121).
[0558]
[0559] ZAP70
[0560]
[0561] Intracellular signaling domains suitable for use in a CAR of the present disclosure include a ZAP70 polypeptide, eg, a polypeptide comprising an amino acid sequence having at least about 85%, at least about 90%, at least approximately 95%, at least approximately 98%, at least approximately 99% or 100%, of amino acid sequence identity relative to a contiguous series of approximately 300 amino acids to approximately 400 amino acids, from approximately 400 amino acids to approximately 500 amino acids or from about 500 amino acids to 619 amino acids, from the following amino acid sequence:
[0562]
[0563]
[0564] TQKAEAACA (SEQ ID NO: 36).
[0565]
[0566] Additional sequences
[0567]
[0568] The first and / or second polypeptide of a particular CAR may further include one or more additional polypeptide domains, said domains including, but not limited to, a signal sequence; an epitopic tag; an affinity domain; and a polypeptide that produces a detectable signal.
[0569]
[0570] Signal sequences
[0571]
[0572] Signal sequences that are suitable for use in a particular CAR, eg, in the first polypeptide of a particular CAR, include any eukaryotic signal sequence, including a naturally occurring signal sequence, a synthetic sequence (eg , produced by the hand of man), etc.
[0573]
[0574] Epitopic label
[0575]
[0576] Suitable epitopic tags include, but are not limited to, hemagglutinin (HA; for example, YPYDVPDYA (SEQ ID NO: 122); FLAG (for example, DYKDDDDK (SEQ ID NO: 123); c-myc (for example, EQKLISEEDL; SEQ ID NO: 4) and the like.
[0577]
[0578] Affinity domain
[0579]
[0580] Affinity domains include peptide sequences that can interact with a binding partner, for example, such as one immobilized on a solid support, useful for identification or purification purposes. DNA sequences encoding multiple consecutive individual amino acids, such as histidine, can be used which when fused to the expressed protein allow one-step purification of the recombinant protein by high-affinity binding to a resin column, such as nickel-sepharose . Exemplary affinity domains include His5 (HHHHH) (SEQ ID NO: 124), HisX6 (HHHHHH) (SEQ ID NO: 125), C-myc (EQKLISEEDL) (SEQ ID NO: 4), Flag (DYKDDDDK ) (SEQ ID NO: 123), StrepTag (WSHPQFEK) (SEQ ID NO: 126), hemagglutinin, for example, HA tag (YPYDVp DYa) (SEQ ID NO: 122), GST, thioredoxin, cellulose binding domain, RYIRS (SEQ ID NO: 127), Phe-His-His-Thr (SEQ ID NO: 128), chitin binding domain, S peptide, T7 peptide, SH2 domain, C-terminus A r N tag, WEAAAREACCRECCARA (SEQ ID NO: 129), metal binding domains, eg, zinc binding domains or calcium binding domains, such as those of calcium binding proteins, eg, calmodulin, troponin C, calcineurin B, chain myosin, recoverin, S-modulin, visinin, VILIP, neurocalcin, hypocalcin, frequency, caltractin, large subunit of calpain, S100 proteins, parvalbumin, calbindin D9K, calbindin D28K and calretinin, inteins, biotin, streptavidin, MyoD, Id, leucine zipper and maltose binding protein sequences.
[0581]
[0582] Polypeptides that produce a detectable signal
[0583]
[0584] Suitable detectable signal-producing proteins include, for example, fluorescent proteins; enzymes that catalyze a reaction that generates a detectable signal as a product; and the like.
[0585]
[0586] Suitable fluorescent proteins include, but are not limited to, green fluorescent protein (GFP) or variants thereof, blue fluorescent variant of GFP (BFP), cyan fluorescent variant of GFP (CFP), yellow fluorescent variant of GFP (YFP), GFP Enhanced (EGFP), Enhanced CFP (ECFP), Enhanced YFP (EYFP), GFPS65T, Esmeralda, Topaz (TYFP), Venus, Citrine, mCitrina, GFPuv, destabilized EGFP (dEGFP), destabilized ECFP (dECFP), destabilized EYFP (dEYFP ), mCFPm, Cerulean, T-Sapphire, CyPet, YPet, mKO, HcRed, t-HcRed, DsRed, DsRed2, DsRed monomer, J-Red, dimer2, t-dimer2 (12), mRFP1, pociloporin, GFP from Renilla , Monster GFP, paGFP, Kaede protein and kindling protein, phycobiliproteins and phycobiliprotein conjugates, including B-phycoerythrin, R-phycoerythrin and allophycocyanin. Other examples of fluorescent proteins include mHoneydew, mBanana, mOrange, dTomato, tdTomato, mTangerine, mStrawberry, mCherry, mGrape1, mRaspberry, mGrape2, mPlum (Shaner et al. (2005) Nat. Methods 2: 905-909) and the like. The use of any one of a number of fluorescent and colored proteins of anthozoan species is suitable, as described, for example, in Matz et al. (1999) Nature Biotechnol.
[0587] 17: 969-973.
[0588]
[0589] Suitable enzymes include, but are not limited to, horseradish peroxidase (HRP), alkaline phosphatase (AP), beta-galactosidase (GAL), glucose-6-phosphate dehydrogenase, beta-N-acetylglucosaminidase, p-glucuronidase, invertase, xanthine oxidase, firefly luciferase, glucose oxidase and the like.
[0590]
[0591] Recombination of sequences
[0592]
[0593] In certain cases, the polypeptide sequences of a CAR, eg, CAR domains, can be rearranged or deleted in a cell by using site-specific recombination technology. In certain embodiments, the cellular activation-related response against a particular CAR can be changed by site-specific recombination, for example, a first intracellular signaling domain of a CAR that triggers a first activation-related response can be exchanged for a second Intracellular signaling domain that triggers a second activation-related response. In certain cases, the response to a particular CAR dimer can be changed by site-specific recombination, for example, a first dimer binding pair that causes dimerization of a CAR in the presence of a first dimer can be exchanged for a second pair binding to dimer that causes CAR dimerization in the presence of a second dimer. As will be apparent to those skilled in the art, site-specific recombination in a cell can be used to exchange any domain or sequence of a CAR for any other domain or sequence, as disclosed herein. As will also be apparent to those skilled in the art, site-specific recombination in a cell can be used to remove any domain or sequence from a CAR. Such exchange and extraction of sequences and domains is known in the art, see, for example, the exchange of domains in signaling bodies as described in Tone et al. (2013) Biotechnology and Bioengineering, 3219-3226, the disclosure of which is disclosed herein by reference. Mechanisms and requirements for performing site-specific recombination in vivo are also known in the art, see, eg, Grindley et al. (2006) Annual Review of Biochemistry, 567-605 and Tropp (2012) Molecular Biology (Jones & Bartlett Publishers, Sudbury, MA), the disclosure of which is incorporated herein by reference.
[0594]
[0595] NUCLEIC ACIDS
[0596]
[0597] The present disclosure provides a nucleic acid comprising a nucleotide sequence encoding the first and / or second conditionally active heterodimeric CAR polypeptide of the present disclosure. A nucleic acid comprising a nucleotide sequence encoding the first and / or second conditionally active heterodimeric CAR polypeptide of the present disclosure will be DNA, including, for example, a recombinant expression vector. A nucleic acid comprising a nucleotide sequence encoding the first and / or second conditionally active heterodimeric CAR polypeptide of the present disclosure will be RNA, eg, Rn synthesized in vitro.
[0598]
[0599] In some cases, a nucleic acid of the present disclosure comprises a nucleotide sequence encoding only the first (and not the second polypeptide) polypeptide of a conditionally active heterodimeric CAR of the present disclosure. In some cases, a nucleic acid of the present disclosure comprises a sequence of nucleotides encoding only the second (and not the first polypeptide) polypeptide of a conditionally active heterodimeric CAR of the present disclosure. In some cases, a nucleic acid of the present disclosure comprises a nucleotide sequence encoding both the first and second polypeptides of a conditionally active heterodimeric CAR of the present disclosure.
[0600]
[0601] In some cases, a particular nucleic acid enables the production of a CAR of the present disclosure, for example, in a mammalian cell. In other cases, a specific nucleic acid makes it possible to amplify the nucleic acid encoding CAR.
[0602]
[0603] A nucleic acid sequence encoding the first and / or second polypeptide of a CAR of the present disclosure can be operably linked to a transcriptional control element, eg, a promoter and an enhancer, etc.
[0604]
[0605] Suitable promoter and enhancer elements are known in the art. For expression in a bacterial cell, suitable promoters include, but are not limited to, lacI, lacZ, T3, T7, gpt, lambda P, and trc. For expression in a eukaryotic cell, suitable promoters include, but are not limited to, the immunoglobulin light and / or heavy chain gene promoter and enhancer elements; the immediate early promoter of cytomegalovirus; the herpes simplex virus thymidine kinase promoter; SV40 early and late promoters; the promoter present in the long terminal repeats of a retrovirus; the mouse metallothionein-I promoter; and various tissue specific promoters known in the art.
[0606]
[0607] Suitable reversible promoters are known in the art, including reversible inducible promoters. Such reversible promoters can be isolated and obtained from various organisms, for example, eukaryotes and prokaryotes. Modification of reversible promoters from one organism for use in a second organism, for example, a first prokaryote and a second eukaryote, a first eukaryote and a second prokaryote, etc., is well known in the art. Such reversible promoters and systems based on said reversible promoters but also comprising additional control proteins include, but are not limited to, promoters regulated by alcohol (eg, promoter of the alcohol dehydrogenase I (alcA) gene, promoters responsive to transactivator proteins alcohol (AlcR), etc.), tetracycline-regulated promoters, (eg, promoter systems including Tet, TetON, TetOFF activators, etc.), steroid-regulated promoters (eg, glucocorticoid receptor promoter systems of rat, human estrogen receptor promoter systems, retinoid promoter systems, thyroid promoter systems, ecdysone promoter systems, mifepristone promoter systems, etc.), metal regulated promoters (eg promoter systems metallothionein, etc.), promoters regulated by pathogenesis (for example, promoters regulated by salicylic acid, promoters re gulated by ethylene, benzothiadiazole-regulated promoters, etc.), temperature-regulated promoters (for example, promoters inducible by heat shock (for example, HSP-70, HSP-90, the soybean heat shock promoter, etc.) , light-regulated promoters, synthetic inducible promoters, and the like.
[0608]
[0609] In some cases, the locus or construct or transgene containing the appropriate promoter is irreversibly activated through induction of an inducible system. Inducible systems for induction of an irreversible active center are well known in the art, eg induction of an irreversible active center may employ Cre-lox mediated recombination (see, eg, Fuhrmann-Benzakein, et al., PNAS (2000) 28: e99), the disclosure of which is incorporated herein by reference. Any suitable combination of recombinase, endonuclease, ligase, recombination sites, etc. can be used. known in the art to generate an irreversibly activatable promoter. Methods, mechanisms, and requirements for performing site-specific recombination, described elsewhere in this document, are well known in the art and are useful for generating irreversibly activated promoters, see, eg, Grindley et al. (2006) Annual Review of Biochemistry, 567-605 and Tropp (2012) Molecular Biology (Jones & Bartlett Publishers, Sudbury, MA), the disclosure of which is incorporated herein by reference.
[0610]
[0611] In some cases, the promoter is a CD8 cell specific promoter, a CD4 cell specific promoter, a neutrophil specific promoter, or a NK specific promoter. For example, a promoter of the CD4 gene can be used; see, eg, Salmon et al. (1993) Proc. Natl. Acad. Sci. USA 90: 7739; and Marodon et al. (2003) Blood 101: 3416. As a further example, a promoter of the CD8 gene can be used. Specific expression in NK cells can be achieved through the use of an Ncr1 promoter (p46); see, for example, Eckelhart et al. (2011) Blood 117: 1565.
[0612]
[0613] In some embodiments, for example, for expression in a yeast cell, a suitable promoter is a constitutive promoter, such as an ADH1 promoter, a PGK1 promoter, an ENO promoter, a PYK1 promoter, and the like; or a regulatable promoter, such as a GAL1 promoter, a GAL10 promoter, an ADH2 promoter, a PHO5 promoter, a CUP1 promoter, a GAL7 promoter, a MET25 promoter, a MET3 promoter, a promoter of CYC1, a HIS3 promoter, an ADH1 promoter, a PGK promoter, a GAPDH promoter, an ADC1 promoter, a TRP1 promoter, a URA3 promoter, a LEU2 promoter, an ENO promoter, a TP1 and AOX1 (for example, for use in Pichia). Selection of the appropriate vector and promoter is within the basic capabilities of one skilled in the art.
[0614] Promoters suitable for use in prokaryotic host cells include, but are not limited to, a bacteriophage T7 RNA polymerase promoter; trp promoter; a lac operon promoter; a hybrid promoter, eg, a hybrid lac / tac promoter, a hybrid tac / trc promoter, trp / lac promoter, T7 / lac promoter; a trc promoter; a tac promoter and the like; an araBAD promoter; in vivo regulated promoters, such as an ssaG promoter or a related promoter (see, eg, US Patent Publication No. 20040131637), a pagC promoter (Pulkkinen and Miller, J. Bacteriol., 1991: 173 (1): 86-93; Alpuche-Aranda et al., PNAS, 1992; 89 (21): 10079-83), a nirB promoter (Harborne et al. (1992) Mol. Micro. 6: 2805-2813 ), and the like (see, eg, Dunstan et al. (1999) Infect. Immun. 67: 5133-5141; McKelvie et al. (2004) Vaccine 22: 3243-3255; and Chatfield et al. (1992) Biotechnol 10: 888-892); a sigma70 promoter, eg, a sigma70 consensus promoter (see, eg, GenBank part numbers AX798980, AX798961 and AX798183); a stationary phase promoter, eg, a dps promoter, a spv promoter, and the like; a promoter from the SPI-2 pathogenic island (see, eg, WO96 / 17951); an actA promoter (see, eg, Shetron-Rama et al. (2002) Infect. Immun. 70: 1087-1096); an rpsM promoter (see, eg, Valdivia and Falkow (1996). Mol. Microbiol. 22: 367); a tet promoter (see, eg, Hillen, W. and Wissmann, A. (1989) In Saenger, W. and Heinemann, U. (eds), Topics in Molecular and Structural Biology, Protein-Nucleic Acid Interaction. Macmillan, London, UK, Volume 10, pp. 143-162); an SP6 promoter (see, eg, Melton et al. (1984) Nucl. Acids Res. 12: 7035); and the like. Strong promoters suitable for use in prokaryotes, such as Escherichia coli, include, but are not limited to, Trc, Tac, T5, T7, and PLambda. Non-limiting examples of operators for use in bacterial host cells include a lactose promoter operator (the Lacl repressor protein changes conformation when in contact with lactose, thereby preventing the Lacl repressor protein from binding to the operator) , a tryptophan promoter operator (when complexed with tryptophan, the TrpR repressor protein has an operator-binding conformation; in the absence of tryptophan, the TrpR repressor protein has a non-operator binding conformation) and a promoter operator tac (see, eg, deBoer et al. (1983) Proc. Natl. Acad. Sci. USA 80: 21-25).
[0615]
[0616] A nucleotide sequence encoding a specific CAR may be present in an expression vector and / or a cloning vector. In cases where a particular CAR comprises two separate polypeptides, nucleotide sequences encoding the two polypeptides can be cloned into the same vector or into separate vectors. An expression vector can include a selection marker, an origin of replication, and other features that enable replication and / or maintenance of the vector. Suitable expression vectors include, for example, plasmids, viral vectors, and the like.
[0617]
[0618] Large numbers of suitable vectors and promoters are known to those of skill in the art; many are commercially available to generate specific recombinant constructs. The following vectors are provided by way of illustration. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene, La Jolla, Calif., USA); pTrc99A, pKK223-3, pKK233-3, pDR540 and pRIT5 (Pharmacia, Uppsala, Sweden). Eukaryotes: pWLneo, pSV2cat, pOG44, PXR1, pSG (Stratagene) pSvK3, pBPv, pMSG and pSVL (Pharmacia).
[0619]
[0620] Expression vectors generally have convenient restriction sites located close to the promoter sequence to enable insertion of nucleic acid sequences encoding heterologous proteins. An operational selection marker may be present on the expression host. Suitable expression vectors include, but are not limited to, viral vectors (eg, vaccinin virus-based viral vectors; polioviruses; adenoviruses (see, eg, Li et al., Invest Opthalmol Vis Sci 35: 25432549, 1994; Borras et al., Gene Ther 6: 515 524, 1999; Li and Davidson, PNAS 92: 7700 7704, 1995; Sakamoto et al., H Gene Ther 5: 1088 1097, 1999; WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655); adeno-associated viruses (see, eg, Ali et al., Hum Gene Ther 9:81 86, 1998, Flannery et al., PNAS 94: 69166921, 1997; Bennett et al., Invest Opthalmol Vis Sci 38: 2857 2863, 1997; Jomary et al., Gene Ther 4: 683 690, 1997, Rolling et al., Hum Gene Ther 10: 641 648, 1999 ; Ali et al., Hum Mol Genet 5: 591 594, 1996; Srivastava in WO 93/09239, Samulski et al., J. Vir. (1989) 63: 3822-3828; Mendelson et al., Virol. (1988) 166: 154-165; and Flotte et al., PNAS (1993) 90: 10613-10617); SV40; herpes simplex virus; human immunodeficiency (see, eg, Miyoshi et al., PNAS 94: 10319 23, 1997; Takahashi et al., J Virol 73: 7812 7816, 1999); a retroviral vector (eg, murine leukemia virus, spleen necrosis virus, and vectors derived from retroviruses, such as Rous sarcoma virus, Harvey sarcoma virus, avian leukosis virus, immunodeficiency virus human, myeloproliferative sarcoma virus and mammary tumor virus); and the like.
[0621]
[0622] As noted above, in some embodiments, a nucleic acid comprising a nucleotide sequence encoding the first and / or second conditionally active heterodimeric CAR polypeptide of the present disclosure will be RNA, eg, RNA synthesized in vitro. Methods for the synthesis of RNA in vitro are known in the art; Any known method can be employed to synthesize RNA comprising a nucleotide sequence encoding the first and / or the second polypeptide of a conditionally active heterodimeric CAR of the present disclosure. Methods for introducing RNA into a host cell are known in the art. See, for example, Zhao et al. (2010) Cancer Res. 15: 9053. The introduction of an RNA comprising a nucleotide sequence encoding the first and / or the second conditionally active heterodimeric CAR polypeptide of the present disclosure into a host cell can be carried out in vitro or ex vivo or in vivo. For example, it can be electroporated to a host cell (eg, an NK cell, a cytotoxic T lymphocyte, etc.) in vitro or ex vivo with RNA comprising a nucleotide sequence encoding the first and / or second conditionally active heterodimeric CAR polypeptide of the present disclosure.
[0623]
[0624] CELLS
[0625]
[0626] The present disclosure provides a mammalian cell that is genetically modified to produce a conditionally active heterodimeric CAR of the present disclosure.
[0627]
[0628] Suitable mammalian cells include primary cells and immortalized cell lines. Suitable mammalian cell lines include human cell lines, non-human primate cell lines, rodent cell lines (eg, mouse, rat), and the like. Suitable mammalian cell lines include, but are not limited to, HeLa cells (eg, American Type Culture Collection (ATCC) # CCL-2), CHO cells (eg, ATCC # CRL96l8, CCL61, CRL9096) , 293 cells (eg ATCC # CRL-1573), Vero cells, cells
[0629] NIH 3t 3 (eg, ATCC # CRL-1658), Huh-7 cells, BHK cells (eg, ATCC # CCL10), PC12 cells
[0630] (ATCC # CRL1721), COS cells, COS-7 cells (ATCC # CRL1651), RAT1 cells, mouse L cells (ATCC # CCLI.3), human embryonic kidney (HEK) cells (ATCC No. CRL1573), HLHepG2 cells, Hut-78, Jurkat, HL-60, NK cell lines (eg, NKL, NK92, and Yt S), and the like.
[0631]
[0632] In some cases, the cell is not an immortalized cell line, but is a cell (eg, a primary cell) obtained from an individual. For example, in some cases, the cell is an immune cell obtained from an individual. As an example, the cell is a T lymphocyte obtained from an individual. By way of further example, the cell is a cytotoxic cell obtained from an individual. By way of further example, the cell is a stem cell or a progenitor cell obtained from an individual.
[0633]
[0634] METHODS TO ACTIVATE AN IMMUNE CELL
[0635]
[0636] The present disclosure provides methods of activating an immune cell in vitro, in vivo, or ex vivo. The methods generally involve contacting an immune cell (in vitro, in vivo or ex vivo) with a dimerizing agent and an antigen, the immune cell being genetically modified to produce a conditionally active heterodimeric CAR of the present disclosure. In the presence of the dimerizing agent and antigen, the conditionally active heterodimeric CAR dimerizes and activates the immune cell, thereby producing an activated immune cell. Immune cells include, for example, a cytotoxic T lymphocyte, an NK cell, a CD4 + T lymphocyte, a regulatory T lymphocyte (Treg), etc.
[0637]
[0638] Contacting the genetically modified immune cell (eg, a T lymphocyte, an NK cell) with a dimerizing agent and a second member of a specific binding pair (eg, an antigen, a ligand, a receptor) can increase the production of a cytokine by the immune cell by at least about 10%, at least about 15%, at least about 20%, at about 25%, at least about 30%, at least about 40%, about 50%, at least about 75%, at least about 2 times, at about 2.5 times, at least about 5 times, at least about 10 times or more than 10 times, compared to the amount of cytokine produced by the immune cell in the absence of the second member of a specific binding pair and / or the dimerizing agent. Cytokines whose production can be increased include, but are not limited to, IL-2 and IFN-y.
[0639]
[0640] Contacting the genetically modified immune cell (eg, a T lymphocyte, an NK cell) with a dimerizing agent and an antigen can increase the production of a cytokine by the immune cell by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about
[0641] 40%, at least about 50%, at least about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times or more than 10 times, compared with the amount of cytokines produced by the immune cell in the absence of the antigen and / or the dimerization agent. Cytokines whose production can be increased include, but are not limited to, IL-2 and IFN-y.
[0642]
[0643] Contacting a genetically modified cytotoxic cell (eg, a cytotoxic T lymphocyte) with a dimerizing agent and a second member of a specific binding pair (eg, an antigen, a ligand, a receptor) may increase activity. cell cytotoxic at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times or more than 10 times, compared to the cytotoxic activity of the cytotoxic cell in the absence of the dimerizing agent.
[0644]
[0645] Contacting a genetically modified cytotoxic cell (eg, cytotoxic T lymphocyte) with a dimerizing agent and an antigen can increase the cytotoxic activity of the cytotoxic cell by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times or more than 10 times, compared to the cytotoxic activity of the cytotoxic cell in the absence of the dimerization.
[0646]
[0647] In other embodiments, for example, depending on the host immune cell, contacting a genetically engineered host cell with a dimerizing agent and an antigen can increase or decrease cell proliferation, cell survival, cell death, and the like.
[0648]
[0649] METHODS TO GENERATE A CONDITIONALLY ACTIVABLE CELL
[0650]
[0651] The present disclosure provides a method of generating a conditionally activatable cell. The method generally involves genetically modifying a mammalian cell with an expression vector or an RNA (eg, in vitro transcribed RNA), which comprises nucleotide sequences encoding a conditionally active heterodimeric CAR of the present disclosure. The genetically modified cell can be conditionally activated in the presence of: a) an antigen to which the first CAR polypeptide binds; and b) a dimerizer (a dimerizing agent). Genetic modification can be carried out in vivo, in vitro or ex vivo. The cell can be an immune cell (for example, a T lymphocyte or an NK cell), a stem cell, a progenitor cell, etc.
[0652]
[0653] In some cases, genetic modification is carried out ex vivo. For example, a T lymphocyte, a stem cell, or an NK cell is obtained from an individual; and the cell obtained from the individual is genetically modified to express a CAR of the present disclosure. The genetically modified cell can be conditionally activated in the presence of: a) an antigen to which the first CAR polypeptide binds; and b) a dimerizer. In some cases, the genetically modified cell is activated ex vivo. In other cases, the genetically modified cell is introduced into an individual (eg, the individual from which the cell was obtained); and the genetically modified cell is activated in vivo, for example, by administering a dimer to the individual. For example, in cases where the antigen is present on the surface of a cell in the individual, there is no need to administer the antigen. The genetically modified cell comes into contact with the antigen present on the surface of a cell in the individual; and, upon administration of a dimerizer to the individual, the genetically modified cell is activated. For example, in cases where the genetically modified cell is a T lymphocyte, the genetically modified cell may display cytotoxicity against a cell that has an antigen on its surface to which CAR binds.
[0654]
[0655] TREATMENT METHODS
[0656]
[0657] The present disclosure provides various methods of treatment using a particular CAR.
[0658]
[0659] Cytotoxicity methods
[0660]
[0661] A CAR of the present disclosure, when present in a T lymphocyte or an NK cell, can mediate cytotoxicity towards a target cell. A CAR of the present disclosure binds to an antigen present in a target cell, thereby mediating the elimination of a target cell by means of a T lymphocyte or an NK cell genetically modified to produce the CAR. The antigen binding domain of CAR binds to an antigen present on the surface of a target cell.
[0662]
[0663] Target cells include, but are not limited to, cancer cells. Therefore, the present disclosure provides methods of eliminating or inhibiting the growth of a cancer target cell, the method involving contacting a cytotoxic immune effector cell (eg, a cytotoxic T lymphocyte or an NK cell) that is genetically modified to produce a specific CAR, such that the T lymphocyte or the NK cell recognizes an antigen present on the surface of a target cancer cell and mediates the elimination of the target cell.
[0664]
[0665] The present disclosure provides a method of treating cancer in an individual having cancer, the method comprising: i) genetically modifying T lymphocytes obtained from the individual with an expression vector comprising nucleotide sequences encoding the conditionally active heterodimeric CAR of the present disclosure, where the conditionally active heterodimeric CAR antigen binding domain is specific for an epitope in a cancer cell in the individual and where the genetic modification is carried out ex vivo; ii) introducing the genetically modified T lymphocytes into the individual; and iii) administering to the individual an effective amount of a dimerization agent, where the dimerization agent induces the dimerization of the conditionally active heterodimeric CAR, where said dimerization enables the activation of the genetically modified T lymphocytes and the elimination of the cancer cell , thereby treating cancer.
[0666]
[0667] Carcinomas that may be susceptible to therapy by a method disclosed herein include, but are not limited to, esophageal carcinoma, hepatocellular carcinoma, basal cell carcinoma (a form of skin cancer), squamous cell carcinoma (various tissues) , bladder carcinoma, transitional cell carcinoma (a malignant neoplasm of the bladder), bronchogenic carcinoma, colon carcinoma, colorectal carcinoma, gastric carcinoma, lung carcinoma, including small cell carcinoma of the lung and non-carcinoma small cell of lung, adrenocortical carcinoma, thyroid carcinoma, pancreatic carcinoma, breast carcinoma, ovarian carcinoma, prostate carcinoma, adenocarcinoma, carcinoma of the sebaceous glands, papillary carcinoma, papillary adenocarcinoma, medullary cystadenocarcinoma renal cell carcinoma, ductal carcinoma in situ or bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical carcinoma of the uterus, uterine carcinoma, testicular carcinoma, osteogenic carcinoma, epithelial carcinoma, and nasopharyngeal carcinoma.
[0668]
[0669] Sarcomas that may be susceptible to therapy by a method disclosed herein include, but are not limited to, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, chordoma, osteogenic sarcoma, osteosarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas.
[0670] Other solid tumors that may be susceptible to therapy by a method disclosed herein include, but are not limited to, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma. .
[0671]
[0672] Leukemias that may be susceptible to therapy by a method disclosed herein include, but are not limited to, a) chronic myeloproliferative syndromes (multipotent hematopoietic stem cell neoplastic disorders); b) acute myelogenous leukemias (neoplastic transformation of a multipotent hematopoietic cell or of a hematopoietic cell of restricted lineage potential; c) chronic lymphocytic leukemias (CLL; immunologically immature and functionally incompetent clonal proliferation of small lymphocytes), including CLL of B lymphocytes, CLL prolymphocytic leukemia of T lymphocytes and hairy cell leukemia; and d) acute lymphoblastic leukemias (characterized by the accumulation of lymphoblasts). Lymphomas that can be treated using one of the present methods include, but are not limited to, B-cell lymphomas (eg, Burkitt's lymphoma); Hodgkin lymphoma; non-Hodgkin lymphoma and the like.
[0673]
[0674] Other cancers that may be susceptible to treatment according to the methods disclosed herein include atypical meningioma (brain), islet cell carcinoma (pancreas), medullary carcinoma (thyroid), mesenchymoma (intestine), hepatocellular carcinoma (liver ), hepatoblastoma (liver), clear cell carcinoma (kidney) and neurofibroma of the mediastinum.
[0675]
[0676] Immunomodulatory methods
[0677]
[0678] One of the present methods can also be used to treat inflammatory conditions and autoimmune diseases. For use in an immunomodulatory method, a specific CAR is expressed in a helper T cell or in a Treg. Immunomodulatory methods include, for example, enhancing an immune response in a mammalian subject to a pathogen; enhance an immune response in a subject who is immunocompromised; reduce an inflammatory response; reducing an immune response in a mammalian subject to an autoantigen, for example, to treat an autoimmune disease; and reducing an immune response in a mammalian subject to a transplanted organ or tissue, to reduce rejection of the organ or tissue.
[0679]
[0680] In cases where the method involves reducing an immune response to an autoantigen, the antigen used to activate CAR is an autoantigen. In cases where the method involves reducing an immune response to a transplanted organ or tissue, the antigen used to activate the CAR is a specific antigen for the transplanted organ.
[0681]
[0682] Formulations, doses and routes of administration
[0683]
[0684] As discussed above, a method of treatment of the present disclosure involves administration to an individual in need of an effective amount of a dimerizing agent and may also involve administration of an antigen.
[0685]
[0686] An "effective amount" of a dimerizing agent is, in some cases, an amount that, when administered in one or more doses to an individual in need, increases the level of cytotoxic activity of a T lymphocyte expressing a particular CAR in at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at less than about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times or more than 10 times, compared to the cytotoxic activity of T lymphocyte in the absence of the agent dimerization.
[0687]
[0688] An "effective amount" of a dimerizing agent is, in some cases, an amount that, when administered in one or more doses to an individual in need, increases the level of cytotoxic activity of an NK cell expressing a particular CAR in at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2 times, at least about 2.5 times, at least about 5 times, at least about 10 times or more than 10 times, compared to the cytotoxic activity of the NK cell in the absence of the dimerizing agent.
[0689]
[0690] An "effective amount" of a dimerizing agent is, in some cases, an amount that, when administered in one or more doses to an individual in need, reduces the number of cancer cells in the individual and / or reduces the tumor mass. in the individual, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75% or more than 75%, compared to the number of cancer cells and / or the tumor mass in the absence of the dimerizing agent.
[0691]
[0692] In some embodiments, an effective amount of a dimerizer is an amount that, when administered alone (eg, as monotherapy) or in combination (eg, in combination therapy) with one or more additional therapeutic agents, in one or more doses , is effective in reducing one or more of the tumor growth rate, the number of cancer cells, and the tumor mass, by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least approximately 25%, at least approximately 30%, at least approximately 40%, at least approximately 50%, at least approximately 60%, at least approximately 70%, at least approximately 80%, at least about 90% or more, compared to the rate of tumor growth, the number of cancer cells, or the tumor mass in the absence of dimerizer treatment.
[0693]
[0694] Formulations
[0695]
[0696] In the present methods, a dimerizer can be administered to the host using any convenient means capable of resulting in the desired therapeutic effect or diagnostic effect. Therefore, the dimerizer can be incorporated into various formulations for therapeutic administration. More particularly, a dimerizer can be formulated into pharmaceutical compositions in combination with suitable pharmaceutically acceptable carriers or diluents and can be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections , inhalants and sprays.
[0697] In pharmaceutical dosage forms, a dimerizer may be administered in the form of its pharmaceutically acceptable salts, or it may also be used alone or in suitable association, as well as in combination, with other pharmaceutically active compounds. The following methods and excipients are merely illustrative and in no way limiting.
[0698]
[0699] Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. Furthermore, if desired, the vehicle may contain minor amounts of auxiliary substances, such as wetting or emulsifying agents or pH buffering agents. The actual methods for preparing such dosage forms are known or will be apparent to those skilled in the art. See, eg, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 17th edition, 1985. In either case, the composition or formulation to be administered will contain an amount of a suitable dimerizer to achieve the desired state in the subject that is being treated.
[0700]
[0701] Pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers, or diluents, are readily accessible to the public. Furthermore, pharmaceutically acceptable auxiliary substances, such as pH adjusting agents and buffers, tonicity adjusting agents, stabilizers, wetting agents, and the like, are readily accessible to the public.
[0702]
[0703] For oral preparations, a dimerizer alone or in combination with suitable additives can be used to prepare tablets, powders, granules or capsules, for example with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or jellies; with disintegrants, such as corn starch, potato starch or sodium carboxymethyl cellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, wetting agents, preservatives and flavoring agents.
[0704]
[0705] A dimerizer can be formulated into injection preparations by dissolving, suspending, or emulsifying it in an aqueous or nonaqueous solvent, such as vegetable oils or the like, synthetic aliphatic acid glycerides, higher aliphatic acid esters, or propylene glycol; and if desired, with conventional additives, such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
[0706]
[0707] Pharmaceutical compositions comprising a dimerizer are prepared by mixing the dimerizer having the desired degree of purity with physiologically acceptable carriers, excipients, stabilizers, surfactants, buffers and / or tonicity agents. Vehicles, excipients, and / or stabilizers are not toxic to receptors at the doses and concentrations used and include buffers such as phosphate, citrate and other organic acids; antioxidants, including ascorbic acid, glutathione, cysteine, methionine, and citric acid; preservatives (such as ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, or combinations thereof); amino acids, such as arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline and combinations thereof; monosaccharides, disaccharides, and other carbohydrates; low molecular weight polypeptides (less than about 10 residues); proteins, such as gelatin or serum albumin; chelating agents such as EDTA; sugars such as trehalose, sucrose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, raffinose, glucosamine, N-methylglucosamine, galactosamine, and neuraminic acid; and / or nonionic surfactants, such as Tween, Brij, Pluronics, Triton-X, or polyethylene glycol (PEG).
[0708]
[0709] The pharmaceutical composition may be in a liquid form, a lyophilized form, or a reconstituted liquid form from a lyophilized form, wherein the lyophilized preparation will be reconstituted with a sterile solution prior to administration. The conventional procedure for reconstituting a lyophilized composition is to add a volume of pure water again (usually equivalent to the volume removed during lyophilization); however, solutions comprising antibacterial agents can be used for the production of pharmaceutical compositions for parenteral administration; see also Chen (1992) Drug Dev Ind Pharm 18, 1311-54.
[0710]
[0711] The term "unit dose form", as used herein, refers to physically discrete units suitable as unit doses for human and animal subjects, each unit containing a predetermined amount of a dimerizer calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle. Specifications for a given dimer may depend on the particular dimer used and the intended effect and the pharmacodynamics associated with each dimer on the host.
[0712]
[0713] In some embodiments, a dimerizer is formulated into a controlled release formulation. Sustained-release preparations can be prepared using methods well known in the art. Suitable examples of sustained release preparations include semipermeable matrices of dimerizer-containing solid hydrophobic polymers in which the matrices are in the form of shaped articles, eg, films or microcapsules. Examples of sustained release matrices include polyesters, copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, hydrogels, polylactides, degradable copolymers of lactic acid-glycolic acid and poly-D- ( -) - 3-hydroxybutyric. Possible loss of biological activity can be prevented by using suitable additives, controlling moisture content and developing specific polymer matrix compositions.
[0714]
[0715] Dosages
[0716]
[0717] An appropriate dose can be determined by an attending physician or other qualified medical personnel, based on various clinical factors. As is known in the medical art, the dose for any patient depends on various factors, including the size of the patient, the body surface area, the age, the specific dimer to be administered, the sex of the patient, the time and the route of administration, the general state of health and other drugs that are being administered concurrently. A dimerizer can be administered in amounts of between 1 ng / kg of body weight and 20 mg / kg of body weight per dose, for example, between 0.1 mg / kg of body weight to 10 mg / kg of body weight, for example , between 0.5 mg / kg of body weight to 5 mg / kg of body weight; however, doses above and below this illustrative range are anticipated, with particular consideration being given to the aforementioned factors. If the regimen is a continuous infusion, it can also be in the range of 1 | jg to 10 mg per kilogram of body weight per minute.
[0718]
[0719] Those of skill in the art will readily appreciate that dosage levels can vary depending on the specific dimerizer, the severity of symptoms, and the subject's susceptibility to side effects. The preferred doses for a given compound can be easily determined by those skilled in the art by various means.
[0720]
[0721] Administration routes
[0722]
[0723] A dimerizer is administered to an individual using any available method and route that is suitable for drug delivery, including in vivo and ex vivo methods, as well as systemic and localized routes of administration.
[0724] Conventional and pharmaceutically acceptable routes of administration include intratumoral, peritumoral, intramuscular, intratracheal, intracranial, subcutaneous, intradermal routes of administration, topical, intravenous, intraarterial, rectal, nasal, oral, and other enteral and parenteral routes. The routes of administration can be combined, if desired, or adjusted depending on the dimerizer and / or the desired effect. A dimerizer can be administered in a single dose or in multiple doses. In some embodiments, a dimerizer is administered orally. In some embodiments, a dimer is administered by an inhalation route. In some embodiments, a dimerizer is administered intranasally. In some embodiments, a dimer is administered locally. In some embodiments, a dimerizer is administered intratumorally. In some embodiments, a peritumor dimerizer. In some embodiments, a dimerizer is administered intracranially. In some embodiments, a dimerizer is administered intravenously.
[0725]
[0726] The agent can be administered to a host using any conventional methods and routes available for the delivery of conventional drugs, including localized or systemic routes. In general, the routes of administration contemplated by the invention include, but are not necessarily limited to, the enteral, parenteral or inhalation routes.
[0727]
[0728] Parenteral routes of administration other than inhalation administration include, but are not necessarily limited to, the topical, transdermal, subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, intratumoral, peritumoral, and intravenous routes, i.e. any administration other than through the alimentary canal. Parenteral administration can be carried out to effect systemic or local delivery of a dimerizer. In case a systemic delivery is desired, administration usually involves systemically absorbed topical or mucosal or invasive administration of the pharmaceutical preparations.
[0729] A dimerizer can also be administered to the subject by enteral administration. Enteral routes of administration include, but are not necessarily limited to, oral and rectal delivery (eg, using a suppository).
[0730] By treatment is meant at least relief of symptoms associated with pathology affecting the host, the term relief being used in a broad sense to refer to at least a reduction in the magnitude of a parameter, eg, symptom, associated with the pathology being treated, such as cancer. As such, treatment also includes situations in which the pathology, or at least the symptoms associated with it, are completely inhibited, for example, prevented from occurring or stopping, for example, ending, such that the host stops suffering from pathology or at least the characteristic symptoms of pathology.
[0731]
[0732] In some embodiments, a dimerizer is administered by injection and / or delivery, for example, to a site in the cerebral artery or directly to brain tissue. A dimerizer can also be administered directly to a target site, for example, by direct injection, by implantation of a drug delivery device, such as an osmotic pump or slow release particle, by biolistic delivery to the target site, etc.
[0733]
[0734] Combination therapy
[0735]
[0736] In some embodiments, a dimerizer is administered as adjuvant therapy for conventional cancer therapy. Conventional cancer therapies include surgery (eg, surgical removal of cancerous tissue), radiation therapy, bone marrow transplantation, chemotherapeutic treatment, antibody treatment, biological response modifier treatment, and certain combinations of the above.
[0737]
[0738] Radiotherapy includes, but is not limited to, X-rays or gamma rays that are delivered through an external source, such as a beam or by implanting small radioactive seeds.
[0739]
[0740] Antibodies suitable for use in cancer treatment include, but are not limited to, naked antibodies, eg trastuzumab (Herceptin), bevacizumab (Avastin ™), cetuximab (Erbitux ™), panitumumab (Vectibix ™), Ipilimumab (Yervoy ™ ), rituximab (Rituxan), alemtuzumab (Lemtrada ™), Ofatumumab (Arzerra ™), Oregovomab (OvaRex ™), Lambrolizumab (MK-3475), pertuzumab (Perjeta ™), ranibizumab (Lucentis ™) etc. and conjugated antibodies, eg, gemtuzumab ozogamycin (Mylortarg ™), Brentuximab vedotin (Adcetris ™), ibritumomab 90Y-labeled tyuxetane (Zevalin ™), 131I-labeled tositumomab (Bexxar ™), etc. Antibodies suitable for use in cancer treatment include, but are not limited to, antibodies raised against tumor associated antigens. Such antigens include, but are not limited to, CD20, CD30, CD33, CD52, EpCAM, CEA, gpA33, mucins, TAG-72, CAIX, PSMA, folate binding protein, gangliosides (eg, GD2, GD3, GM2, etc. .), Le y, VEGF, VEGFR, alpha-V-beta-3 integrin, alpha-5-beta-1 integrin, EGFR, ERBB2, ERBB3, MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, FAP, tenascin, etc.
[0741]
[0742] Biological response modifiers suitable for use in connection with the methods of the present disclosure include, but are not limited to, (1) inhibitors of tyrosine kinase (RTK) activity; (2) serine / threonine kinase activity inhibitors; (3) antagonists of tumor associated antigens, such as antibodies that specifically bind to a tumor antigen; (4) apoptosis receptor agonists; (5) interleukin-2; (6) interferon-a .; (7) interferon-Y; (8) colony stimulating factors; (9) angiogenesis inhibitors; and (10) antagonists of tumor necrosis factor.
[0743]
[0744] Chemotherapeutic agents are non-peptidic (i.e., non-protein) compounds that reduce cancer cell proliferation and encompass cytotoxic agents and cytostatic agents. Non-limiting examples of chemotherapeutic agents include alkylating agents, nitrosoureas, antimetabolites, anti-tumor antibiotics, plant alkaloids (vinca), and steroid hormones.
[0745]
[0746] Agents that reduce cell proliferation are known and widely used in the art. Such agents include alkylating agents, such as nitrogen mustards, nitrosoureas, ethyleneimine derivatives, alkyl sulfonates and triazenes, including, but not limited to, mechlorethamine, cyclophosphamide (Cytoxan ™), melphalane (L-sarcolysin), carmustine (BCNU), semustine (methyl-CCNU), streptozocin, chlorozotocin, mustard uracil, chlormethine, ifosfamide, chlorambucil, pipobromanum, triethylene melamine, triethylene phosphoramine, busulfan, dacarbazine, and temozolomide.
[0747]
[0748] Antimetabolite agents include folic acid analogs, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors, including, but not limited to, cytarabine (CYTOSAR-U), cytosine arabinoside, fluorouracil (5-FU), floxuridine (FudR) , 6-thioguanine, 6-mercaptopurine (6-MP), pentostatin, 5-fluorouracil (5-FU), methotrexate, 10-propargyl-5,8-didesazafolate (PDDF, CB3717), 5,8-didesazatetrahydrofolic acid (DDATHF ), leucovorin, fludarabine phosphate, pentostatin, and gemcitabine.
[0749]
[0750] Suitable natural products and their derivatives, (for example, vinca alkaloids, anti-tumor antibiotics, enzymes, lymphokines, and epipodophyllotoxins) include, but are not limited to, Ara-C, paclitaxel (Taxol®), docetaxel (Taxotere®), deoxychoformycin , mitomycin-C, L-asparaginase, azathioprine; brequinar; alkaloids, for example, vincristine, vinblastine, vinorelbine, vindesine, etc .; podophyllotoxins, eg etoposide, teniposide, etc .; antibiotics, eg anthracycline, daunorubicin hydrochloride (daunomycin, rubidomycin, cerubidine), idarubicin, doxorubicin, epirubicin, and morpholino derivatives, etc .; Defenoxyzone biscyclopeptides, eg dactinomycin; basic glycopeptides, eg bleomycin; anthraquinone glycosides, eg, plicamycin (mithramycin); anthracenodones, eg, mitoxantrone; azirinopyrrolo indoldiones, eg mitomycin; macrocyclic immunosuppressants, eg cyclosporine, FK-506 (tacrolimus, prograf), rapamycin, etc .; and the like.
[0751] Other antiproliferative cytotoxic agents are navelbeno, CPT-11, anastrazol, letrazol, capecitabina, reloxafina, cyclophosphamide, ifosamida, and droloxafina.
[0752]
[0753] Also suitable is the use of agents that affect microtubules that have antiproliferative activity and include, but are not limited to, allocolchicine (NSC 406042), halicondrine B (NSC 609395), colchicine (NSC 757), colchicine derivatives (for example, NSC 33410), dolastatin 10 (NSC 376128), maytansine (NSC 153858), rhizoxine (NSC 332598), paclitaxel (Taxol®), derivatives of Taxol®, docetaxel (Taxotere®), thiocolchicine (NSC 361792), trityl cysteine, sulfate vinblastine, vincristine sulfate, natural and synthetic epothilones, including, but not limited to, epothilone A, epothilone B, discodermolide; estramustine, nocodazole and the like.
[0754]
[0755] Hormone modulators and steroids (including synthetic analogues) that are suitable for use include, but are not limited to, adrenocorticosteoids, eg prednisone, dexamethasone, etc .; estrogens and progestins, for example hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, estradiol, clomiphene, tamoxifen; etc.; and adrenocortical suppressors, for example, aminoglutethimide; 17aetinilestradiol; Diethylstilbestrol, Testosterone, Fluoxymesterone, Dromostanolone Propionate, Testolactone, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimoretin, Zinc (Medroxyprogesterone, Fluoride) Estrogens stimulate proliferation and differentiation, therefore, compounds that bind to the estrogen receptor are used to block this activity. Corticosteroids can inhibit the proliferation of T lymphocytes.
[0756]
[0757] Other chemotherapeutic agents include metal complexes, eg, cisplatin (cis-DDP), carboplatin, etc .; ureas, eg hydroxyurea; and hydrazines, for example, N-methylhydrazine; epidophyllotoxin; a topoisomerase inhibitor; procarbazine; mitoxantrone; leucovorin; tegafur; etc. Other antiproliferative agents of interest include immunosuppressants, for example, mycophenolic acid, thalidomide, deoxyspergualine, azasporin, leflunomide, mizoribine, azaspiran (SKF 105685); Iressa® (ZD 1839, 4- (3-chloro-4-fluorophenylamino) -7-methoxy-6- (3- (4-morpholinyl) propoxy) quinazoline); etc.
[0758]
[0759] "Taxanes" include paclitaxel, as well as any active derivatives or prodrugs of taxanes. "Paclitaxel" (which is to be understood herein to include analogs, formulations, and derivatives such as, for example, docetaxel, TAXOL ™, TAXOTERE ™ (a formulation of docetaxel), 10-deacetyl analogues of paclitaxel, and analogs of 3 Paclitaxel 'N-desbenzoyl-3'Nt-butoxycarbonyl) can be easily prepared using techniques known to those skilled in the art (see also WO 94/07882, WO 94/07881, WO 94/07880, WO 94/07876, WO 93/23555, WO 93/10076; US Patent Nos. 5,294,637; 5,283,253; 5,279,949; 5,274,137; 5,202,448; 5,200,534; 5,229,529; and document EP 590,267) or are obtained from a number of commercial sources, including, for example, Sigma Chemical Co., St. Louis, Mo. (T7402 from Taxus brevifolia; or T-1912 from Taxus yannanensis).
[0760]
[0761] It should be understood that paclitaxel refers not only to the chemically available common form of paclitaxel, but to analogs and derivatives (eg Taxotere ™ docetaxel, as noted above) and to paclitaxel conjugates (eg paclitaxel-PEG, paclitaxel -dextran or paclitaxel-xylose).
[0762]
[0763] Also included within the term "taxane" are a number of known derivatives, including both hydrophilic and hydrophobic derivatives. Taxane derivatives include, but are not limited to, the galactose and mannose derivatives described in International Patent Application No. WO99 / 18113; piperazine derivatives and others described in WO 99/14209; the taxane derivatives described in WO 99/09021, WO 98/22451 and in US Patent No. 5,869,680; the 6-thio derivatives described in WO 98/28288; the sulfenamide derivatives described in US Patent No. 5,821,263; and the taxol derivatives described in US Patent No. 5,415,869. Furthermore, it includes prodrugs of paclitaxel including, but not limited to, those described in WO 98/58927; WO 98/13059; and in United States Patent No. 5,824,701.
[0764]
[0765] SUITABLE SUBJECTS FOR TREATMENT
[0766]
[0767] There are several subjects suitable for treatment with one of the present methods of treating cancer. Suitable subjects include any individual, for example, a human or non-human animal that has cancer, has been diagnosed with cancer, is at risk of developing cancer, has had cancer, or is at risk of recurrence of cancer, who has been treated with an agent other than a cancer dimer and who has not had a response to that treatment or who has been treated with an agent other than a cancer dimer but has had a recurrence after an initial response to such treatment.
[0768] Suitable subjects for treatment with one of the present immunomodulatory methods include individuals who have an autoimmune disorder; individuals who are recipients of organ or tissue transplants; and the like; individuals who are immunocompromised; and individuals who are infected with a pathogen.
[0769] Examples
[0770]
[0771] The following examples are set out to provide those of ordinary skill in the art with a full disclosure and description of how to prepare and use the present invention and are not intended to limit the scope of what the inventors consider their invention and are intended to represent that the experiments below are all or the only experiments carried out. Efforts have been made to ensure accuracy with respect to the numbers used (eg quantities, temperature, etc.) but some errors and experimental deviations should be taken into account. Unless otherwise noted, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure. Conventional abbreviations can be used, eg, bp, base pairs; kb, kilobases; pl, picoliters; s, seconds; min, minutes; h, hours; aa, amino acids; kb, kilobases; bp, base pairs; nt, nucleotides; i.m., intramuscularly; i.p., intraperitoneally; s.c., subcutaneously; i.v., intravenously; and the like.
[0772]
[0773] Example 1: CAR generation
[0774]
[0775] MATERIALS AND METHODS
[0776]
[0777] Human anti-CD19 scFv was selected as the antigen recognition domain in CARs during the design optimization process. Figures 18A and 18B summarize the molecular structure of each CAR consisting of two numerically identified polypeptides. All membrane-anchored polypeptides are disulfide-linked homodimers. Membrane-anchored polypeptides are represented as monomers for graphic simplicity.
[0778] Generation of the CAR constructions
[0779]
[0780] The sequence encoding the anti-human CD19 scFv was cloned from a construct. The 4-1BB costimulation and ITAM CD3 zeta signaling chains were cloned from the cDNAs supplied by Open Biosystems. The sequences encoding FKBP and FRB were cloned from plasmids supplied by Addgene.
[0781]
[0782] Conventional molecular cloning techniques (polymerase chain reaction (PRC), restriction digestion, ligation, etc.) were applied to generate lentiviral expression plasmids.
[0783]
[0784] Target and effector cell culture conditions
[0785]
[0786] Primary human CD8 + T lymphocytes were isolated from blood from anonymous donors after their apheresis (Trima remnants from Blood Centers of the Pacific, San Francisco, CA) by negative selection using RosetteSep Human CD8 + T lymphocyte enrichment cocktail (STEMCELL Technologies No. 15063) as approved by the Institutional Review Committee of the University. Cells were grown in human T lymphocyte medium, consisting of X-VIVO15 (Lonza, # 04-418Q), 5% human AB serum (Valley Biomedical Inc., # HP1022), N-acetyl L -10 mM cysteine (Sigma-Aldrich, # A9165) and 100 Ul / ml of recombinant human IL-2 (NCI / BRB Preclinical Repository). A Jurkat cell line expressing green fluorescent protein (GFP) was maintained after NFAT activation in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), penicillin, and streptomycin. Target K562 cells from U. Penn were cultured in IMDM supplemented with 10% FBS.
[0787]
[0788] Target and effector cell modification with lentivirus
[0789] Pantropic VSV-G pseudotyped lentivirus was produced in Lenti-X 293T cells (Clontech Laboratories, # 632180) co-transfected with an expression vector for the pHR'SIN: CSW transgene, the viral packaging plasmids pCMVdR8.91, and pMD2.G using Lipofectamine LTX (Life Technologies, # 15338). The supernatant from the infection medium was collected 48 hours after transfection and was used directly for transduction.
[0790]
[0791] Twenty-four hours after virus transduction, human T lymphocytes were activated using human CD3 / CD28-T activating Dynabeads (Life Technologies, # 111-31D) at a cell: bead ratio of 1: 3. Jurkat and K562 cells were divided 1 ~ 2 days before to ensure that the cultures were in the logarithmic phase at the time of transduction. The transduced Jurkat and K562 cells were cultured for at least 7 days before carrying out the experiments. Primary T lymphocytes were maintained at ~ 10A6 / ml in human T lymphocyte medium for approximately two weeks until the cells returned to the resting state. Expression levels of encoded CARs in the lentiviral constructs were quantitated by detecting fluorophore-conjugated antibodies or fluorescent reporter proteins using a flow cytometer.
[0792]
[0793] Quantification of IL-2 production and NFAT activity
[0794]
[0795] CAR expressing CD4 + Jurkat T lymphocytes were mixed with K562 cognate or non-cognate target cells from U. Penn at an effector: target ratio of 1: 2. The A / C rapalog heterodimerizer (Clontech Laboratories, # 635055) was serially diluted in medium and added to the reaction mixtures. After 20-24 hours incubation, culture supernatants were collected and analyzed with the BD OptEIA Human IL-2 ELISA Set (BD Biosciences, # 555190). Flow cytometry was performed to quantify NFAT-dependent GFP indicator expression in Jurkat cells as a separate indicator of CAR activity.
[0796]
[0797] Redirected cytotoxicity assay based on flow cytometry
[0798]
[0799] K562 cognate and non-cognate target cells were genetically engineered to express different fluorescent proteins so that both cell types in a mixture were quantified by flow cytometry. The target cell types were mixed at a 1: 1 ratio and co-incubated with human primary effector T c D + lymphocytes at an effector: target ratio of 5: 2. 100 IU / ml human IL-2 and various amounts of the rapalog (Clontech Laboratories, # 635055) were added to the reaction mixtures. After 24 hours of incubation, samples were centrifuged at 400g for 5 minutes. The cell pellet was resuspended in Wash Buffer (PBS 0.5% BSA 0.1% Sodium Azide) and fixed with an equal volume of BD Cytofix (BD, Cat # 554655) prior to flow cytometry. Ratios of surviving cognate target cells to non-cognate target cells were calculated for each sample to list the redirected cytotoxic activities of the effector cells.
[0800]
[0801] RESULTS
[0802]
[0803] IL-2 production caused by the various CAR constructs was evaluated. The data is presented in figure 12.
[0804]
[0805] Figure 12. IL-2 production triggered by five variants of CAR active center. Effector = CAR genetically engineered human CD4 + Jurkat T lymphocytes. Target = K562 cell lines with or without the related CD19 antigen. Amounts of IL-2 secreted by effector cells were quantified by enzyme-linked immunosorbent assay (ELISA).
[0806]
[0807] Figure 13. IL-2 production by Jurkat control lines in an experiment equal to that described in Figure 12. The "125" construct encodes a conventional control currently used in clinical trials.
[0808]
[0809] Figure 14. Comparison between "122 206" and "197 206" in a separate experiment under conditions identical to those described in Figure 12.
[0810]
[0811] Figure 15 demonstrates the pharmacologically titrable cytotoxicity conferred by the CAR active center "197 + 206". In the presence of the small molecule rapalog, CAR effectively mediates redirected cytotoxicity against cognate target cells. At high doses of rapalog, this active CAR center can signal with the same strength as conventional "125" CAR. Effector = human CD8 + T lymphocytes modified with CAR or a control vector. Target = fluorescent derivatives of K562 cell lines expressing the human CD19 cognate antigen or the non-cognate human mesothelin antigen.
[0812]
[0813] Figure 16 depicts data for CARs constructed with the Zap70 cytoplasmic tyrosine kinase from the T-lymphocyte receptor pathway as an intracellular signaling domain.
[0814]
[0815] Figure 16 shows data from modified Jurkat cells with various variants of CAR active centers. Jurkat cells were incubated together with K562 target cells with or without the cognate antigen (CD19) and the indicated concentrations of rapalog. As a component of CAR, Zap70 kinase (first and second structures on the left showing a "199") was effective as ITAM (third structure from the left showing a "168") to activate the NFAT function. Addition of the 4-1BB signaling domain increased the surface expression of the antigen recognition portion of the receptor and resulted in stronger signaling by "197 + 199". A CAR without signaling (last from the left) was included as a negative control.
[0816]
[0817] Example 2: CAR targeting mesothelin
[0818]
[0819] MATERIALS AND METHODS
[0820]
[0821] A series of chimeric antigen receptor constructs were prepared and tested. The constructs shown herein encode three different human anti-mesothelin scFv as antigen recognition domains. Figures 19A, 19B and 19C summarize the molecular structure of each anti-human mesothelin CAR, each CAR comprising two polypeptides. The intercellular portion of each anti-human mesothelin CAR comprises two costimulatory domains 4-1BB, a dimerizer binding pair FKBP and FRB and an intracellular signaling domain ITAM. The three different antigen recognition domains shown in this case are HN1 antimesothelin scFv, scFv SS1, and scFv m912. All membrane-anchored polypeptides are disulfide-linked homodimers.
[0822]
[0823] Generation of the CAR constructions
[0824]
[0825] Sequences encoding anti-mesothelin were either cloned from constructs or synthesized by gene assembly by PCR. The 4-1BB costimulation and ITAM CD3 zeta signaling chains were cloned from the cDNAs supplied by Open Biosystems. The coding sequences of scFv HN1, scFv SS1 and scFv m912 were synthesized by PCR and, in some cases, optimized by codons. The sequences encoding FKBP and FRB were cloned from Addgene plasmids.
[0826]
[0827] Conventional molecular cloning techniques (polymerase chain reaction (PRC), restriction digestion, ligation, etc.) were applied to generate lentiviral expression plasmids.
[0828]
[0829] Target and effector cell culture conditions
[0830]
[0831] A Jurkat cell line expressing GFP was maintained after NFAT activation in RPMI-1640 medium supplemented with 10% FBS, penicillin, and streptomycin. K562 target cells were grown in IMDM supplemented with 10% fetal bovine serum (FBS).
[0832]
[0833] Target and effector cell modification with lentivirus
[0834]
[0835] Pantropic VSV-G pseudotyped lentivirus was produced in Lenti-X 293T cells (Clontech Laboratories, # 632180) co-transfected with an expression vector for the pHR'SIN: CSW transgene, the viral packaging plasmids pCMVdR8.91, and pMD2.G using Lipofectamine LTX (Life Technologies, # 15338). The supernatant from the infection medium was collected 48 hours after transfection and was used directly for transduction.
[0836]
[0837] Jurkat and K562 cells were divided 1 ~ 2 days before to ensure that the cultures were in the logarithmic phase at the time of transduction. The transduced Jurkat and K562 cells were cultured for at least 7 days before carrying out the experiments. Expression levels of encoded CARs in the lentiviral constructs were quantitated by detecting fluorophore-conjugated antibodies or fluorescent reporter proteins using a flow cytometer.
[0838]
[0839] Quantification of IL-2 production
[0840]
[0841] CAR expressing CD4 + Jurkat T lymphocytes were mixed with K562 cognate or non-cognate target cells at an effector: target ratio of 1: 2. The A / C rapalog heterodimerizer (Clontech Laboratories, # 635055) was serially diluted in medium and added to the reaction mixtures. After 20-24 hours of incubation, the culture supernatants were collected and analyzed with the BD OptEIA Human IL-2 ELISA Set (BD Biosciences, # 555190).
[0842]
[0843] RESULTS
[0844]
[0845] IL-2 production caused by anti-mesothelin CAR constructs was evaluated. The data is presented in Figures 19D-F.
[0846]
[0847] Figure 19. IL-2 production triggered by the active center variants of CAR scFv HN1 (Fig. 19D), scFv SS1 (Fig. 19E) and scFv m912 (Fig. 19F). IL-2 production was measured by a conventional CAR (Fig. 19G, construct # 358) and included by comparison to CAR active centers (Fig. 19D). Effector = CAR genetically engineered human CD4 + Jurkat T lymphocytes. Target = K562 cell lines with or without the cognate mesothelin antigen. Amounts of IL-2 secreted by effector cells were quantified by enzyme-linked immunosorbent assay (ELISA).
[0848] Example 3: Gibberellic acid as a dimer of CAR active centers
[0849] MATERIALS AND METHODS
[0850] Figure 20A summarizes the molecular structure of the object gibberellic acid CAR dimer. The antigen-binding portion comprises the anti-human CD19 scFv. The intracellular portion comprises two 4-1BB costimulatory domains, a GID1 and GAI dimerizer binding pair and an ITAM intracellular signaling domain. All membrane-anchored polypeptides are disulfide-linked homodimers.
[0851] Generation of the CAR constructions
[0852] The sequences encoding the gibberellic acid dimerizer CAR were cloned from constructs. The anti-CD19 scFv was cloned from a plasmid. The 4-1BB costimulation and ITAM CD3 zeta signaling chains were cloned from the cDNAs supplied by Open Biosystems. The sequences encoding GID1 and GAI were cloned from Addgene plasmids. Conventional molecular cloning techniques (polymerase chain reaction (PRC), restriction digestion, ligation, etc.) were applied to generate lentiviral expression plasmids.
[0853] Target and effector cell culture conditions
[0854] A Jurkat cell line expressing GFP was maintained after NFAT activation in RPMI-1640 medium supplemented with 10% FBS, penicillin, and streptomycin. K562 target cells were grown in IMDM supplemented with 10% fetal bovine serum (FBS).
[0855] Target and effector cell modification with lentivirus
[0856] Pantropic VSV-G pseudotyped lentivirus was produced in Lenti-X 293T cells (Clontech Laboratories, # 632180) co-transfected with an expression vector for the pHR 'SIN: CSW transgene, the viral packaging plasmids pCMVdR8.91, and pMD2.G using Lipofectamine LTX (Life Technologies, # 15338). The supernatant from the infection medium was collected 48 hours after transfection and was used directly for transduction.
[0857] Jurkat and K562 cells were divided 1 ~ 2 days before to ensure that the cultures were in the logarithmic phase at the time of transduction. The transduced Jurkat and K562 cells were cultured for at least 7 days before carrying out the experiments. Expression levels of encoded CARs in the lentiviral constructs were quantitated by detecting fluorophore-conjugated antibodies or fluorescent reporter proteins using a flow cytometer.
[0858] Quantification of IL-2 production
[0859] CAR expressing CD4 + Jurkat T lymphocytes were mixed with K562 cognate or non-cognate target cells at an effector: target ratio of 1: 2. Gibberellic acid 3-acetoxymethyl ester (Gibberellic Acid-3 AM) previously dissolved in ethanol (Toronto Research Chemicals, # G377500) was diluted in growth medium and added to the reaction mixtures. Gibberellic acid (Gibberellic acid-3 AM) was used at 10 mM. After 20-24 hours incubation, culture supernatants were collected and analyzed with the BD OptEIA Human IL-2 ELISA Set (BD Biosciences, # 555190).
[0860] RESULTS
[0861] IL-2 production caused by the construction of gibberellic acid dimerizer CAR was evaluated. The data is presented in figure 20.
[0862] Figure 20. IL-2 production triggered by the gibberellic acid dimerizer CAR variant (Fig. 20B). IL-2 production was measured by a conventional CAR (Fig. 20C, construct "125") and included by comparison to the active CAR centers. Effector = CAR genetically engineered human CD4 + Jurkat T lymphocytes. Target = K562 cell lines with or without the related CD19 antigen. Amounts of IL-2 secreted by effector cells were quantified by enzyme-linked immunosorbent assay (ELISA).
[0863] Example 4: Active CAR centers with various costimulatory domains
[0864] MATERIALS AND METHODS
[0865] A series of chimeric antigen receptor constructs were prepared essentially as described in Example 1, except that several costimulatory domains were exchanged for costimulatory domains 4-1BB. Figures 21A and 21B summarize the molecular structure of the CARs described in this example.

权利要求:
Claims (15)
[1]
1. A conditionally active heterodimeric chimeric antigen (CAR) receptor comprising:
a first polypeptide comprising an antigen-binding domain comprising a single-chain antibody variable region that specifically binds CD19 or an antigen expressed by a B lymphocyte, a first member of the dimerization pair, and a first transmembrane domain; and
a second polypeptide comprising a second member of a dimerization pair, a second transmembrane domain, and an intracellular signaling domain;
wherein a dimerizing agent dimerizes the heterodimeric CAR when a cell expresses the first and second polypeptides with the dimerizing agent bound between members of the dimerization pair of the first and second polypeptides.
[2]
2. The conditionally active heterodimeric CAR of claim 1, wherein the intracellular signaling domain is a CD3-zeta intracellular signaling domain or a ZAP-70 intracellular signaling domain.
[3]
3. The conditionally active heterodimeric CAR of claims 1 or 2, wherein the first polypeptide, the second polypeptide, or both comprise a costimulatory polypeptide.
[4]
4. The conditionally active heterodimeric CAR of claim 3, wherein the costimulatory polypeptide (or polypeptides) is selected from the group consisting of: 4-1BB, CD28, ICOS, OX-40, BTlA, Cd 27, c D30, GlTR and HVEM.
[5]
5. The conditionally active heterodimeric CAR of any one of the preceding claims, wherein the first and second members of the dimerization pair are selected from:
a) FK506 binding protein (FKBP) and FKBP-rapamycin-associated protein (FRB);
b) a gibberellic acid insensitive protein (GAI) and a gibberellin receptor protein (GID1);
c) FKBP and catalytic subunit A of calcineurin (CnA);
d) an abscisic acid receptor protein (PYL) and an abscisic acid insensitive protein (ABI);
e) FKBP and cyclophilin; and
f) FK506 binding protein (FKBP) and FKBP;
g) gyrase B (GyrB) and GyrB;
h) dihydrofolate reductase (DHFR) and DHFR; and
i) DmrB and DmrB.
[6]
6. One or more nucleic acid molecules encoding the conditionally active heterodimeric CAR of any one of the preceding claims.
[7]
7. A conditionally active heterodimeric chimeric antigen receptor (CAR) comprising:
a first polypeptide comprising:
a first member of a specific binding pair;
a first member of a dimerization pair; and
a first transmembrane domain; and
a second polypeptide comprising:
a second member of a dimerization pair;
a second transmembrane domain; and
an intracellular signaling domain,
wherein the first and second members of the dimerization pair dimerize in the presence of a dimerizing agent.
[8]
8. The conditionally active heterodimeric CAR of claim 7, wherein the first polypeptide, the second polypeptide, or both first and second polypeptides further comprise a costimulatory domain.
[9]
9. The conditionally active heterodimeric CAR of claims 7 or 8, wherein the first transmembrane domain is interposed between the first member of a specific binding pair and the first member of the dimerization pair, and the second member of the dimerization pair is interposed between the second transmembrane domain and the intracellular signaling domain.
[10]
10. A first conditionally active heterodimeric chimeric antigen (CAR) receptor polypeptide, the polypeptide comprising:
a first member of a specific binding pair;
a first member of a dimerization pair; and
a transmembrane domain, where, when the first polypeptide is expressed by a cell expressing a conditionally active heterodimeric second CAR polypeptide in the presence of a dimerization agent, the dimerization agent is bound between members of the dimerization pair, dimerizing from thus the first and second polypeptides, and wherein the second polypeptide comprises:
a second member of the dimerization pair;
a transmembrane domain; and
an intracellular signaling domain.
[11]
11. The first polypeptide of claim 10, further comprising a costimulatory domain, optionally selected from the group consisting of: 4-1BB, CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR and HVEM.
[12]
12. The first polypeptide of claims 10 or 11, wherein the transmembrane domain is interposed between the first member of a specific binding pair and the first member of a dimerization pair.
[13]
13. A second conditionally active heterodimeric chimeric antigen (CAR) receptor polypeptide, the polypeptide comprising:
a second member of a dimerization pair;
a transmembrane domain; and
an intracellular signaling domain, where, when the second polypeptide is expressed by a cell expressing a conditionally active heterodimeric CAR first polypeptide in the presence of a dimerization agent, the dimerization agent is bound between members of the dimerization pair, thereby dimerizing the first and second polypeptides, and wherein the first polypeptide comprises:
a first member of a specific binding pair;
a first member of the dimerization pair; and
a transmembrane domain.
[14]
14. The second polypeptide of claim 13, further comprising a costimulatory domain, optionally selected from the group consisting of: 4-1BB, CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR and HVe M.
[15]
15. The second polypeptide of claims 13 or 14, wherein the second member of the dimerization pair is interposed between the transmembrane domain and the intracellular signaling domain.

类似技术:

---

公开号 | 公开日 | 专利标题

---

ES2758227T3|2020-05-04|Chimeric antigen receptor and methods of using it

---

JP7014843B2|2022-02-01|Chimeric antigen receptor and how to use it

---

NZ710925B2|2021-06-29|Chimeric antigen receptor and methods of use thereof

---

NZ750521A|2021-03-26|Chimeric antigen receptor and methods of use thereof

---

NZ750521B2|2021-06-29|Chimeric antigen receptor and methods of use thereof

同族专利:

---

公开号 | 公开日

---

PL2956175T3|2018-05-30|

---

EP3881868A1|2021-09-22|

---

US20170340672A1|2017-11-30|

---

AU2014216130A1|2015-08-27|

---

EP3300745B1|2019-09-11|

---

AU2018201102A1|2018-03-08|

---

PT3613439T|2021-05-12|

---

US10888581B2|2021-01-12|

---

CN105142677B|2019-08-30|

---

HK1253407A1|2019-06-14|

---

US20180042963A1|2018-02-15|

---

ES2758227T3|2020-05-04|

---

LT3300745T|2019-12-10|

---

PL3300745T3|2020-03-31|

---

AU2021204054A1|2021-07-08|

---

EP3613439A1|2020-02-26|

---

SI3300745T1|2020-01-31|

---

DK2956175T3|2017-11-27|

---

US9821012B2|2017-11-21|

---

JP6450690B2|2019-01-09|

---

PL3613439T3|2021-11-22|

---

EP3300745A1|2018-04-04|

---

JP6687712B2|2020-04-28|

---

ES2653487T3|2018-02-07|

---

AU2019246785B2|2021-04-08|

---

NZ710925A|2021-03-26|

---

US20180085401A1|2018-03-29|

---

US20170143765A1|2017-05-25|

---

EP3300745B9|2020-04-15|

---

HRP20192123T1|2020-02-21|

---

KR102332790B1|2021-12-01|

---

KR20150119134A|2015-10-23|

---

HK1218625A1|2017-03-03|

---

KR20210147101A|2021-12-06|

---

AU2019246785A1|2019-10-31|

---

DK3300745T3|2019-11-04|

---

EP2956175A1|2015-12-23|

---

JP2020121982A|2020-08-13|

---

HUE036250T2|2018-06-28|

---

CN110423282A|2019-11-08|

---

ES2868247T3|2021-10-21|

---

MX2019013498A|2020-01-20|

---

US20210196757A1|2021-07-01|

---

EP3613439B1|2021-04-07|

---

SI3613439T1|2021-11-30|

---

US20150368342A1|2015-12-24|

---

US20160185862A1|2016-06-30|

---

IL240472D0|2015-09-24|

---

MX369545B|2019-11-12|

---

MX2015010522A|2016-06-23|

---

AU2014216130B2|2017-11-16|

---

PT3300745T|2019-11-27|

---

CA2901115A1|2014-08-21|

---

KR102132246B1|2020-07-09|

---

PT2956175T|2017-12-26|

---

IL240472A|2020-02-27|

---

LT2956175T|2017-12-11|

---

EP2956175A4|2016-08-24|

---

US9587020B2|2017-03-07|

---

US10105391B2|2018-10-23|

---

KR20190131152A|2019-11-25|

---

EP2956175B1|2017-10-04|

---

IL272279D0|2020-02-27|

---

BR112015019640A2|2021-08-03|

---

KR20200083682A|2020-07-08|

---

NO2929995T3|2018-02-03|

---

WO2014127261A1|2014-08-21|

---

KR102064230B1|2020-01-13|

---

US10632152B2|2020-04-28|

---

US20200237824A1|2020-07-30|

---

JP2016508518A|2016-03-22|

---

JP2019068822A|2019-05-09|

---

HUE047487T2|2020-04-28|

---

CN105142677A|2015-12-09|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US5677425A|1987-09-04|1997-10-14|Celltech Therapeutics Limited|Recombinant antibody|

---

US5906936A|1988-05-04|1999-05-25|Yeda Research And Development Co. Ltd.|Endowing lymphocytes with antibody specificity|

---

US5585362A|1989-08-22|1996-12-17|The Regents Of The University Of Michigan|Adenovirus vectors for gene therapy|

---

CA2052928A1|1990-10-15|1992-04-16|John J. Siekierka|Genes encoding the human fk-506 binding protein and a.s. cerevisiae homolog, fkb1 and their expression|

---

AU643109B2|1990-12-14|1993-11-04|Cell Genesys, Inc.|Chimeric chains for receptor-associated signal transduction pathways|

---

TW197439B|1991-04-04|1993-01-01|Ueno Pharmaceutics Applic Res Co Ltd|

---

AT237694T|1991-08-20|2003-05-15|Us Gov Health & Human Serv|ADENOVIRUS MEDIATED GENTRANSFER INTO THE GASTROINTESTINAL TRACT|

---

US5283253A|1991-09-23|1994-02-01|Florida State University|Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them|

---

US5252479A|1991-11-08|1993-10-12|Research Corporation Technologies, Inc.|Safe vector for gene therapy|

---

WO1993010076A1|1991-11-22|1993-05-27|The University Of Mississippi|Synthesis and optical resolution of the taxol side chain and related compounds|

---

CA2100808A1|1992-10-01|1994-04-02|Vittorio Farina|Deoxy paclitaxels|

---

US5200534A|1992-03-13|1993-04-06|University Of Florida|Process for the preparation of taxol and 10-deacetyltaxol|

---

FR2688514B1|1992-03-16|1994-12-30|Centre Nat Rech Scient|

---

IL104570D0|1992-03-18|1993-05-13|Yeda Res & Dev|Chimeric genes and cells transformed therewith|

---

WO1993023555A1|1992-05-21|1993-11-25|The Penn State Research Foundation|Cultured taxus tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds|

---

US5274137A|1992-06-23|1993-12-28|Nicolaou K C|Intermediates for preparation of taxols|

---

US5294637A|1992-07-01|1994-03-15|Bristol-Myers Squibb Company|Fluoro taxols|

---

US5202448A|1992-08-14|1993-04-13|Napro Biotherapeutics, Inc.|Processes of converting taxanes into baccatin III|

---

FR2696461B1|1992-10-05|1994-11-10|Rhone Poulenc Rorer Sa|New derivatives of taxol analogs, their preparation and compositions containing them.|

---

FR2696464B1|1992-10-05|1994-11-10|Rhone Poulenc Rorer Sa|New esterification process for baccatin III and 10-deacetyl baccatin III.|

---

FR2696463B1|1992-10-05|1994-11-25|Rhone Poulenc Rorer Sa|Process for obtaining 10-deacetyl baccatin III.|

---

FR2696458B1|1992-10-05|1994-11-10|Rhone Poulenc Rorer Sa|Process for the preparation of taxane derivatives.|

---

FR2696462B1|1992-10-05|1994-11-25|Rhone Poulenc Rorer Sa|Process for obtaining 10-deacetyl baccatin III.|

---

EP1024198A3|1992-12-03|2002-05-29|Genzyme Corporation|Pseudo-adenoviral vectors for the gene therapy of haemophiliae|

---

US5279949A|1992-12-07|1994-01-18|Board Of Trustees Operating Michigan State University|Process for the isolation and purification of taxol and taxanes from Taxus spp|

---

US5834266A|1993-02-12|1998-11-10|President & Fellows Of Harvard College|Regulated apoptosis|

---

CN1119876A|1993-02-12|1996-04-03|莱兰斯坦福初级大学评议会|Regulated transcription of targeted genes and other biological events|

---

US5830462A|1993-02-12|1998-11-03|President & Fellows Of Harvard College|Regulated transcription of targeted genes and other biological events|

---

US5869337A|1993-02-12|1999-02-09|President And Fellows Of Harvard College|Regulated transcription of targeted genes and other biological events|

---

US5310903A|1993-03-05|1994-05-10|Merck & Co., Inc.|Imidazolidyl rapamycin derivatives|

---

AU687829B2|1993-06-24|1998-03-05|Advec, Inc.|Adenovirus vectors for gene therapy|

---

US5824701A|1993-10-20|1998-10-20|Enzon, Inc.|Taxane-based prodrugs|

---

AT314482T|1993-10-25|2006-01-15|Canji Inc|RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE|

---

US5415869A|1993-11-12|1995-05-16|The Research Foundation Of State University Of New York|Taxol formulation|

---

US5527907A|1993-11-19|1996-06-18|Abbott Laboratories|Macrolide immunomodulators|

---

US5525610A|1994-03-31|1996-06-11|American Home Products Corporation|42-Epi-rapamycin and pharmaceutical compositions thereof|

---

US5362718A|1994-04-18|1994-11-08|American Home Products Corporation|Rapamycin hydroxyesters|

---

US20030036654A1|1994-08-18|2003-02-20|Holt Dennis A.|Synthetic multimerizing agents|

---

US6150527A|1994-08-18|2000-11-21|Ariad Pharmaceuticals, Inc.|Synthetic multimerizing agents|

---

US6133456A|1994-08-18|2000-10-17|Ariad Gene Therapeutics, Inc.|Synthetic multimerizing agents|

---

KR100445103B1|1994-12-09|2004-12-04|임페리얼 컬리지 이노베이션스 리미티드|identification|

---

US5712149A|1995-02-03|1998-01-27|Cell Genesys, Inc.|Chimeric receptor molecules for delivery of co-stimulatory signals|

---

WO1999036553A2|1998-01-15|1999-07-22|Ariad Gene Therapeutics, Inc.|Regulation of biological events using multimeric chimeric proteins|

---

US6187757B1|1995-06-07|2001-02-13|Ariad Pharmaceuticals, Inc.|Regulation of biological events using novel compounds|

---

CA2219080A1|1995-06-07|1996-12-27|Ariad Gene Therapeutics, Inc.|Rapamycin-based regulation of biological events|

---

GB9526131D0|1995-12-21|1996-02-21|Celltech Therapeutics Ltd|Recombinant chimeric receptors|

---

WO1998008833A1|1996-08-26|1998-03-05|Bristol-Myers Squibb Company|Sulfenamide taxane derivatives|

---

EP0961619A4|1996-09-27|2001-09-26|Squibb Bristol Myers Co|Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells|

---

AU4966597A|1996-11-19|1998-06-10|Daiichi Pharmaceutical Co., Ltd.|Taxol derivatives|

---

US5977386A|1996-12-24|1999-11-02|Bristol-Myers Squibb Company|6-thio-substituted paclitaxels|

---

CA2294606A1|1997-06-20|1998-12-30|Baker Norton Pharmaceuticals, Inc.|Soluble prodrugs of paclitaxel|

---

US7288665B1|1997-08-18|2007-10-30|Florida State University|Process for selective derivatization of taxanes|

---

JPH1192468A|1997-09-17|1999-04-06|Yakult Honsha Co Ltd|New taxane derivative|

---

JP4153660B2|1997-10-08|2008-09-24|株式会社横浜国際バイオ研究所|Taxoid derivative and method for producing the same|

---

WO2000023573A2|1998-10-20|2000-04-27|City Of Hope|Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies|

---

CN1293081C|1999-08-24|2007-01-03|阿里亚德基因治疗公司|28-epirapalogs|

---

GB9925854D0|1999-11-01|1999-12-29|Celltech Therapeutics Ltd|Biological products|

---

US7514239B2|2000-03-28|2009-04-07|Amgen Inc.|Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof|

---

US6916846B2|2000-05-12|2005-07-12|Merck & Co. Inc.|Coumermycin analogs as chemical dimerizers of chimeric proteins|

---

GB0025307D0|2000-10-16|2000-11-29|Celltech Chiroscience Ltd|Biological products|

---

JP5312721B2|2000-11-07|2013-10-09|シティ・オブ・ホープ|CD19-specific redirecting immune cells|

---

GB0105402D0|2001-03-05|2001-04-18|Inpharmatica Ltd|Novel proteins|

---

GB0105924D0|2001-03-09|2001-04-25|Microscience Ltd|Promoter|

---

WO2003078575A2|2002-03-11|2003-09-25|The Johns Hopkins University|Molecular switches and methods for making and using the same|

---

US7446190B2|2002-05-28|2008-11-04|Sloan-Kettering Institute For Cancer Research|Nucleic acids encoding chimeric T cell receptors|

---

EP1641927B1|2003-02-18|2015-07-08|Baylor College of Medicine|Induced activation in dendritic cells|

---

US20050113564A1|2003-11-05|2005-05-26|St. Jude Children's Research Hospital|Chimeric receptors with 4-1BB stimulatory signaling domain|

---

US7435596B2|2004-11-04|2008-10-14|St. Jude Children's Research Hospital, Inc.|Modified cell line and method for expansion of NK cell|

---

US7994298B2|2004-09-24|2011-08-09|Trustees Of Dartmouth College|Chimeric NK receptor and methods for treating cancer|

---

US8236925B1|2005-08-26|2012-08-07|University Of Minnesota|Protein nanorings|

---

AT503861B1|2006-07-05|2008-06-15|F Star Biotech Forsch & Entw|METHOD FOR MANIPULATING T-CELL RECEPTORS|

---

WO2011053825A2|2009-10-30|2011-05-05|The United States Of America, As Represented By The Secretary, Department Of Health And Human Services|Compositions and methods for the treatment or prevention of mitochondrial diseases|

---

EA022984B1|2009-12-29|2016-04-29|Эмерджент Продакт Дивелопмент Сиэтл, Ллс|Ron binding constructs and methods of use thereof|

---

AU2011232435B2|2010-03-23|2016-01-28|Intrexon Corporation|Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof|

---

EP2558571A4|2010-04-16|2014-09-24|Immune Disease Inst Inc|Sustained polypeptide expression from synthetic, modified rnas and uses thereof|

---

WO2011146862A1|2010-05-21|2011-11-24|Bellicum Pharmaceuticals, Inc.|Methods for inducing selective apoptosis|

---

CN103201293B|2010-09-08|2016-04-27|哈洛齐梅公司|The method of assessment and qualification or development condition active therapeutic protein|

---

FR2968013A1|2010-11-29|2012-06-01|Cis Bio Int|METHOD OF CONDITIONALLY RETAINING A PROTEIN OF INTEREST IN THE ENDOPLASMIC RETICULUM|

---

MX347078B|2010-12-09|2017-04-10|Univ Pennsylvania|Use of chimeric antigen receptor-modified t cells to treat cancer.|

---

CN103442768A|2011-01-18|2013-12-11|宾夕法尼亚大学董事会|Compositions and methods for treating cancer|

---

KR20210050590A|2012-05-25|2021-05-07|셀렉티스|Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy|

---

BR112015004522A2|2012-09-04|2017-11-21|Cellectis|multi-chain chimeric antigen receptor and uses of these|

---

WO2014055657A1|2012-10-05|2014-04-10|The Trustees Of The University Of Pennsylvania|Use of a trans-signaling approach in chimeric antigen receptors|

---

KR102132246B1|2013-02-15|2020-07-09|더 리젠츠 오브 더 유니버시티 오브 캘리포니아|Chimeric Antigen Receptor and Methods of Use Thereof|

---

JP6541639B2|2013-03-14|2019-07-10|ベリカム ファーマシューティカルズ， インコーポレイテッド|Methods to control T cell proliferation|

---

EP3623380A1|2013-03-15|2020-03-18|Michael C. Milone|Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy|

---

WO2015057852A1|2013-10-15|2015-04-23|The California Institute For Biomedical Research|Chimeric antigen receptor t cell switches and uses thereof|

---

JP6793902B2|2013-12-20|2020-12-02|ノバルティス アーゲー|Adjustable chimeric antigen receptor|

---

US10934346B2|2014-02-14|2021-03-02|Bellicum Pharmaceuticals, Inc.|Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12|

---

EP3119425B1|2014-03-15|2020-09-23|Novartis AG|Regulatable chimeric antigen receptor|

---

GB201405845D0|2014-04-01|2014-05-14|Ucl Business Plc|Signalling system|

---

JP2017531430A|2014-10-07|2017-10-26|セレクティスＣｅｌｌｅｃｔｉｓ|Method for modulating the activity of immune cells induced by CAR|

---

WO2017087723A1|2015-11-19|2017-05-26|The Regents Of The University Of California|Conditionally repressible immune cell receptors and methods of use thereof|

---

CA3004491A1|2016-01-08|2017-07-13|The Regents Of The University Of California|Conditionally active heterodimeric polypeptides and methods of use thereof|KR20210050590A|2012-05-25|2021-05-07|셀렉티스|Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy|

---

SG11201505858VA|2013-01-28|2015-09-29|St Jude Childrens Res Hospital|A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease|

---

KR102132246B1|2013-02-15|2020-07-09|더 리젠츠 오브 더 유니버시티 오브 캘리포니아|Chimeric Antigen Receptor and Methods of Use Thereof|

---

JP6541639B2|2013-03-14|2019-07-10|ベリカム ファーマシューティカルズ， インコーポレイテッド|Methods to control T cell proliferation|

---

EP3623380A1|2013-03-15|2020-03-18|Michael C. Milone|Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy|

---

US10196444B2|2013-07-29|2019-02-05|Bluebird Bio, Inc.|Multipartite signaling proteins and uses thereof|

---

JP6793902B2|2013-12-20|2020-12-02|ノバルティス アーゲー|Adjustable chimeric antigen receptor|

---

WO2015107075A1|2014-01-14|2015-07-23|Cellectis|Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish|

---

US10934346B2|2014-02-14|2021-03-02|Bellicum Pharmaceuticals, Inc.|Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12|

---

EP3119425B1|2014-03-15|2020-09-23|Novartis AG|Regulatable chimeric antigen receptor|

---

GB201405845D0|2014-04-01|2014-05-14|Ucl Business Plc|Signalling system|

---

SG10202109752XA|2014-04-07|2021-10-28|Novartis Ag|Treatment of cancer using anti-cd19 chimeric antigen receptor|

---

CN112175911A|2014-05-15|2021-01-05|新加坡国立大学|Modified natural killer cells and uses thereof|

---

WO2016014530A1|2014-07-21|2016-01-28|Novartis Ag|Combinations of low, immune enhancing. doses of mtor inhibitors and cars|

---

US20170211055A1|2014-07-21|2017-07-27|Novartis Ag|Sortase synthesized chimeric antigen receptors|

---

EP3660042A1|2014-07-31|2020-06-03|Novartis AG|Subset-optimized chimeric antigen receptor-containing t-cells|

---

AU2015308818B2|2014-08-28|2021-02-25|Bioatla Llc|Conditionally active chimeric antigen receptors for modified T-cells|

---

EP3847191A2|2018-09-07|2021-07-14|BioAtla, Inc.|Conditionally active chimeric antigen receptors for modified t-cells|

---

US11111288B2|2014-08-28|2021-09-07|Bioatla, Inc.|Conditionally active chimeric antigen receptors for modified t-cells|

---

EP2990416B1|2014-08-29|2018-06-20|GEMoaB Monoclonals GmbH|Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders|

---

GB201415347D0|2014-08-29|2014-10-15|Ucl Business Plc|Signalling system|

---

US10888608B2|2014-09-02|2021-01-12|Bellicum Pharmaceuticals, Inc.|Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides|

---

BR112017005390A2|2014-09-17|2017-12-12|Novartis Ag|target cytotoxic cells with chimeric receptors for adoptive immunotherapy|

---

JP2017532325A|2014-10-03|2017-11-02|イエール ユニバーシティ|Modification of the innate immune system for anticancer therapy|

---

JP2017531430A|2014-10-07|2017-10-26|セレクティスＣｅｌｌｅｃｔｉｓ|Method for modulating the activity of immune cells induced by CAR|

---

RU2743657C2|2014-10-08|2021-02-20|Новартис Аг|Biomarkers predicting a therapeutic response to therapy with a chimeric antigen receptor, and use thereof|

---

ES2692206T3|2014-11-26|2018-11-30|Miltenyi Biotec Gmbh|Combined immunotherapy of antigen and hematopoietic recognition receptors for the treatment of diseases|

---

EA201791210A1|2014-12-02|2017-11-30|Роджер Уилльямс Хоспитал|METHODS AND COMPOSITIONS FOR CANCER TREATMENT|

---

RU2020120613A|2014-12-05|2021-12-06|Мемориал Слоан-Кеттеринг Кэнсер Сентер|ANTIBODIES TARGETING A RECEPTOR BINDED WITH G-PROTEINS AND METHODS OF THEIR APPLICATION|

---

KR20170109537A|2014-12-05|2017-09-29|메모리얼 슬로안-케터링 캔서 센터|Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof|

---

EP3608408A1|2014-12-15|2020-02-12|Bellicum Pharmaceuticals, Inc.|Methods for controlled activation or elimination of therapeutic cells|

---

EP3851450A1|2014-12-19|2021-07-21|ETH Zürich|Chimeric antigen receptors and methods of use|

---

WO2016098078A2|2014-12-19|2016-06-23|Novartis Ag|Dimerization switches and uses thereof|

---

PT3237436T|2014-12-24|2019-08-05|Aadigen Llc|Peptides and nanoparticles for intracellular delivery of molecules|

---

GB201501936D0|2015-02-05|2015-03-25|Ucl Business Plc|Signalling system|

---

GB201503133D0|2015-02-24|2015-04-08|Ucl Business Plc And Syncona Partners Llp|Chimeric protein|

---

JP2018513692A|2015-02-27|2018-05-31|アイセル・ジーン・セラピューティクス・エルエルシー|Construction of chimeric antibody receptorstargeting hematologic tumors and methods of use thereof|

---

US10195272B2|2015-03-02|2019-02-05|The Nemours Foundation|Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases|

---

GB201504840D0|2015-03-23|2015-05-06|Ucl Business Plc|Chimeric antigen receptor|

---

US11261232B2|2015-04-02|2022-03-01|Memorial Sloan Kettering Cancer Center|TNFRSF14 / HVEM proteins and methods of use thereof|

---

RU2752918C2|2015-04-08|2021-08-11|Новартис Аг|Cd20 therapy, cd22 therapy and combination therapy with cells expressing chimeric antigen receptork cd19|

---

EP3283113A4|2015-04-15|2018-12-05|The California Institute for Biomedical Research|Optimized pne-based chimeric receptor t cell switches and uses thereof|

---

JP2018516592A|2015-04-17|2018-06-28|デイビッド・マクスウエル・バレットＤａｖｉｄ Ｍａｘｗｅｌｌ ＢＡＲＲＥＴＴ|Methods for improving efficacy and proliferation of chimeric antigen receptor expressing cells|

---

GB201507115D0|2015-04-27|2015-06-10|Ucl Business Plc|Nucleic Acid Construct|

---

GB201507119D0|2015-04-27|2015-06-10|Ucl Business Plc|Nucleic Acid Construct|

---

GB201507111D0|2015-04-27|2015-06-10|Ucl Business Plc|Nucleic acid construct|

---

EP3447075A3|2015-05-15|2019-05-29|The General Hospital Corporation|Antagonistic anti-tumor necrosis factor receptor superfamily antibodies|

---

EA202090931A3|2015-05-18|2020-10-30|Тср2 Терапьютикс Инк.|COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH HYBRID PROTEINS|

---

US11173179B2|2015-06-25|2021-11-16|Icell Gene Therapeutics Llc|Chimeric antigen receptortargeting multiple antigens, compositions and methods of use thereof|

---

AU2016283102B2|2015-06-25|2021-03-11|Icell Gene Therapeutics Llc|Chimeric antigen receptors , compositions and methods of use thereof|

---

AU2016297014B2|2015-07-21|2021-06-17|Novartis Ag|Methods for improving the efficacy and expansion of immune cells|

---

GB201513540D0|2015-07-31|2015-09-16|King S College London|Therapeutic agents|

---

EP3575403A1|2015-08-05|2019-12-04|Yoo Young Pharm Co., Ltd.|Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed|

---

CA2995036A1|2015-08-06|2017-02-09|Dana-Farber Cancer Institute, Inc.|Tunable endogenous protein degradation|

---

MX2018001533A|2015-08-24|2018-03-15|Cellectis|Chimeric antigen receptors with integrated controllable functions.|

---

EA201890611A1|2015-09-01|2018-08-31|Те Риджентс Оф Те Юниверсити Оф Калифорния|LIBRARIES OF MODULAR POLYPEPTIDES AND METHODS FOR THEIR RECEPTION AND APPLICATION|

---

JP6905163B2|2015-09-03|2021-07-21|ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア|Biomarkers that predict cytokine release syndrome|

---

CA2999037A1|2015-09-23|2017-03-30|Cytoimmune Therapeutics, LLC|Flt3 directed car cells for immunotherapy|

---

WO2017069958A2|2015-10-09|2017-04-27|The Brigham And Women's Hospital, Inc.|Modulation of novel immune checkpoint targets|

---

WO2017075451A1|2015-10-28|2017-05-04|The Broad Institute Inc.|Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1|

---

WO2017075465A1|2015-10-28|2017-05-04|The Broad Institute Inc.|Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3|

---

US11001622B2|2015-11-19|2021-05-11|The Brigham And Women's Hospital, Inc.|Method of treating autoimmune disease with lymphocyte antigen CD5-likeprotein|

---

WO2017087723A1|2015-11-19|2017-05-26|The Regents Of The University Of California|Conditionally repressible immune cell receptors and methods of use thereof|

---

KR20180075689A|2015-11-23|2018-07-04|트르스티스 오브 보스톤 유니버시티|Methods and compositions for chimeric antigen receptors|

---

US20170199961A1|2015-12-16|2017-07-13|Gritstone Oncology, Inc.|Neoantigen Identification, Manufacture, and Use|

---

EP3184548A1|2015-12-23|2017-06-28|Miltenyi Biotec GmbH|Chimeric antigen receptor with cytokine receptor activating or blocking domain|

---

CA3004491A1|2016-01-08|2017-07-13|The Regents Of The University Of California|Conditionally active heterodimeric polypeptides and methods of use thereof|

---

MX2018008344A|2016-01-11|2018-12-06|Univ Leland Stanford Junior|Chimeric proteins and methods of regulating gene expression.|

---

KR20180095719A|2016-01-11|2018-08-27|더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티|Chimeric proteins and methods of immunotherapy|

---

CN105567640A|2016-01-27|2016-05-11|苏州佰通生物科技有限公司|Chimeric antigen receptor adipose-derived stem cell and preparation method thereof|

---

GB201602563D0|2016-02-12|2016-03-30|Autolus Ltd|Signalling system|

---

GB201602571D0|2016-02-12|2016-03-30|Autolus Ltd|Signalling system|

---

US10871490B2|2016-02-29|2020-12-22|Multenyi Biotec, gmbH|Assay for detection of chimeric antigen receptor T cells|

---

CA3018382A1|2016-03-29|2017-10-05|University Of Southern California|Chimeric antigen receptors targeting cancer|

---

EP3436037A4|2016-03-31|2019-12-04|University of Southern California|A highly sensitive and specific luciferase based reporter assay for antigen detection|

---

JP2019513370A|2016-04-01|2019-05-30|カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａ|Chimeric receptor and method of using the same|

---

SG10201912515XA|2016-04-01|2020-02-27|Kite Pharma Inc|Bcma binding molecules and methods of use thereof|

---

SG11201808622SA|2016-04-01|2018-10-30|Amgen Inc|Chimeric receptors to flt3 and methods of use thereof|

---

MX2018012017A|2016-04-01|2019-07-04|Kite Pharma Inc|Chimeric antigen and t cell receptors and methods of use.|

---

AU2017250773A1|2016-04-14|2018-11-08|2Seventy Bio, Inc.|Salvage chimeric antigen receptor systems|

---

EP3464375A2|2016-06-02|2019-04-10|Novartis AG|Therapeutic regimens for chimeric antigen receptor - expressing cells|

---

WO2018026953A1|2016-08-02|2018-02-08|TCR2 Therapeutics Inc.|Compositions and methods for tcr reprogramming using fusion proteins|

---

WO2018027197A1|2016-08-04|2018-02-08|Memorial Sloan-Kettering Cancer Center|Cancer antigen targets and uses thereof|

---

WO2018045034A1|2016-08-30|2018-03-08|Promab Biotechnologies, Inc.|Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain|

---

US20180064758A1|2016-09-05|2018-03-08|Ucl Business Plc|Chimeric antigen receptor|

---

CN107793483B|2016-09-06|2019-08-23|伍志强|Chimeric antigen receptor and its gene and recombinant expression carrier, CARMSLN-NKT cell and its preparation method and application|

---

US20190262399A1|2016-09-07|2019-08-29|The Broad Institute, Inc.|Compositions and methods for evaluating and modulating immune responses|

---

US10683355B2|2016-09-16|2020-06-16|Kissei Pharmaceutical Co., Ltd.|Genetically-modified cells and method for producing same|

---

WO2018067991A1|2016-10-07|2018-04-12|The Brigham And Women's Hospital, Inc.|Modulation of novel immune checkpoint targets|

---

AU2017341048A1|2016-10-07|2019-05-23|TCR2 Therapeutics Inc.|Compositions and methods for T-cell receptors reprogramming using fusion proteins|

---

CN110225927A|2016-10-07|2019-09-10|诺华股份有限公司|Chimeric antigen receptor for treating cancer|

---

CN107058315B|2016-12-08|2019-11-08|上海优卡迪生物医药科技有限公司|Strike the siRNA for subtracting people PD-1, recombinant expression CAR-T carrier and its construction method and application|

---

AU2017378153A1|2016-12-13|2019-06-13|Seattle Children's Hospital |Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo|

---

WO2018112266A1|2016-12-14|2018-06-21|The Board Of Trustees Of The Leland Stanford Junior University|Il-13 superkine: immune cell targeting constructs and methods of use thereof|

---

US20190328787A1|2017-01-10|2019-10-31|The General Hospital Corporation|T cells expressing a chimeric antigen receptor|

---

CN107573419A|2017-01-24|2018-01-12|深圳市体内生物医药科技有限公司|A kind of nucleic acid molecules for strengthening T cell antitumor activity|

---

CN111386263A|2017-02-08|2020-07-07|达纳-法伯癌症研究所有限公司|Modulation of chimeric antigen receptors|

---

TW201837175A|2017-03-13|2018-10-16|美商凱特製藥公司|Chimeric antigen receptors for melanoma and uses thereof|

---

JOP20180027A1|2017-03-28|2019-01-30|Cell Design Labs Inc|Chimeric polypeptides and methods of altering the membrane localization of the same|

---

JOP20180042A1|2017-04-24|2019-01-30|Kite Pharma Inc|Humanized Antigen-Binding Domains and Methods of Use|

---

JP2020520236A|2017-05-15|2020-07-09|オートラス リミテッド|Cells containing chimeric antigen receptor |

---

CN107141356B|2017-06-07|2020-03-13|胜武（北京）生物科技有限公司|Photoinduced dimer type chimeric antigen receptor|

---

CN107446937B|2017-09-05|2020-12-25|深圳华云生物技术有限公司|Chimeric antigen receptor, expression gene thereof, photo-controlled chimeric antigen receptor modified T cell and application thereof|

---

CN111315769A|2017-09-06|2020-06-19|加州理工学院|Dual-function receptor for signaling and antigen presentation |

---

AU2018335266A1|2017-09-22|2020-02-06|H. Lee Moffitt Cancer Center And Research Institute, Inc.|Chimeric antigen receptors with enhanced NFκB signaling|

---

CN109553686A|2017-09-26|2019-04-02|南京安吉生物科技有限公司|The novel regulatable double Chimeric antigen receptor T cells of one kind and its construction method and application|

---

GB201715918D0|2017-09-29|2017-11-15|Tc Biopharm Ltd|Modified CAR-T|

---

WO2019075112A1|2017-10-10|2019-04-18|Gritstone Oncology, Inc.|Neoantigen identification using hotspots|

---

US20200370012A1|2017-10-25|2020-11-26|Novartis Ag|Methods of making chimeric antigen receptor-expressing cells|

---

EP3710471A1|2017-11-16|2020-09-23|Kite Pharma, Inc.|Modified chimeric antigen receptors and methods of use|

---

MA51157A|2017-12-14|2020-10-21|Bluebird Bio Inc|DARIC INTERLEUKIN RECEPTORS|

---

WO2019115818A2|2017-12-14|2019-06-20|Celyad S.A.|Pooling signaling and costimulatory domains in flexible car design|

---

EP3502130A1|2017-12-20|2019-06-26|St. Anna Kinderkrebsforschung|Ligand regulated protein-protein interaction system|

---

CN111542535A|2017-12-20|2020-08-14|圣安娜儿童癌症研究中心|Ligand-regulated protein-protein interaction systems|

---

EP3728322A1|2017-12-22|2020-10-28|Cell Design Labs, Inc.|Single- and multi-chain chimeric antigen receptors|

---

BR112020011017A2|2017-12-22|2020-11-17|Fate Therapeutics, Inc.|enhanced immune effector cells and their use|

---

EP3735425A1|2018-01-04|2020-11-11|Miltenyi Biotec B.V. & Co. KG|Chimeric antigen receptor specific for bdca2 antigen|

---

CN108017717B|2018-01-24|2019-08-16|首都医科大学宣武医院|A kind of Chimeric antigen receptor and its application for the amplification of external efficiently and directionally|

---

WO2019157496A1|2018-02-12|2019-08-15|University Of Florida Researchfoundation, Inc.|Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a|

---

CA3090793A1|2018-02-16|2019-08-22|Kite Pharma, Inc.|Modified pluripotent stem cells and methods of making and use|

---

AU2019247830A1|2018-04-06|2020-10-22|The Regents Of The University Of California|Trans-antigen targeting in heterogeneous cancers and methods of use thereof|

---

EA202092417A1|2018-04-10|2021-01-26|Амген Инк.|CHIMERIC RECEPTORS TO DLL3 AND METHODS OF THEIR APPLICATION|

---

CN108410908B|2018-04-12|2021-08-03|吉林大学|Method for regulating cell pathway by using plant hormone GA and small molecular substance PAC|

---

WO2019197676A1|2018-04-13|2019-10-17|Ludwig Institute For Cancer Research Ltd|Heterodimeric inactivatable chimeric antigen receptors|

---

WO2019203600A1|2018-04-18|2019-10-24|앱클론|Switch molecule and switchable chimeric antigen receptor|

---

WO2019210207A2|2018-04-27|2019-10-31|The Trustees Of The University Of Pennsylvania|Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis|

---

EP3788369A1|2018-05-01|2021-03-10|Novartis Ag|Biomarkers for evaluating car-t cells to predict clinical outcome|

---

WO2019227003A1|2018-05-25|2019-11-28|Novartis Ag|Combination therapy with chimeric antigen receptortherapies|

---

US20210371932A1|2018-06-01|2021-12-02|Massachusetts Institute Of Technology|Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients|

---

WO2019232523A1|2018-06-01|2019-12-05|The Board Of Trustees Of The Leland Stanford Junior University|Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof|

---

US20210277148A1|2018-07-18|2021-09-09|Amgen Inc.|Chimeric receptors to steap1 and methods of use thereof|

---

SG11202101204TA|2018-08-09|2021-03-30|Juno Therapeutics Inc|Processes for generating engineered cells and compositions thereof|

---

CN112639083A|2018-08-31|2021-04-09|诺华股份有限公司|Method for producing cells expressing chimeric antigen receptor|

---

WO2020047449A2|2018-08-31|2020-03-05|Novartis Ag|Methods of making chimeric antigen receptor-expressing cells|

---

EP3856779A1|2018-09-28|2021-08-04|Novartis AG|Cd22 chimeric antigen receptortherapies|

---

EP3856782A1|2018-09-28|2021-08-04|Novartis AG|Cd19 chimeric antigen receptorand cd22 car combination therapies|

---

WO2020072700A1|2018-10-02|2020-04-09|Dana-Farber Cancer Institute, Inc.|Hla single allele lines|

---

JP2022504191A|2018-10-05|2022-01-13|ザンクト アンナ キンダークレプスフォルシュング|Chimeric antigen receptorgroup|

---

EP3632460A1|2018-10-05|2020-04-08|St. Anna Kinderkrebsforschung|A group of chimeric antigen receptors |

---

US20210386781A1|2018-10-05|2021-12-16|St. Anna Kinderkrebsforschung|A group of chimeric antigen receptors |

---

EP3632461A1|2018-10-05|2020-04-08|St. Anna Kinderkrebsforschung|A group of chimeric antigen receptors |

---

US20210379057A1|2018-10-16|2021-12-09|Massachusetts Institute Of Technology|Nutlin-3a for use in treating a mycobacterium tuberculosis infection|

---

AU2019394940A1|2018-12-05|2021-06-24|Genentech, Inc.|Diagnostic methods and compositions for cancer immunotherapy|

---

WO2020118305A1|2018-12-07|2020-06-11|The Trustees Of Columbia University In The City Of New York|Muc4 car-t cells for treating cancer|

---

CN113412117A|2018-12-12|2021-09-17|凯德药业股份有限公司|Chimeric antigens and T cell receptors and methods of use|

---

US20220062394A1|2018-12-17|2022-03-03|The Broad Institute, Inc.|Methods for identifying neoantigens|

---

WO2020141106A1|2019-01-03|2020-07-09|Kemijski Institut|Engineered externally regulated artificial transcription regulatory system based on engineered nfat|

---

CA3124444A1|2019-01-23|2020-07-30|Miltenyi Biotec B.V. & Co. KG|A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject|

---

CN113543799A|2019-03-01|2021-10-22|艾洛基治疗公司|Chimeric antigen receptor and binding agents targeting DLL3|

---

KR20210137085A|2019-03-05|2021-11-17|엔카르타, 인크.|CD19 induced chimeric antigen receptor and use thereof in immunotherapy|

---

WO2020186101A1|2019-03-12|2020-09-17|The Broad Institute, Inc.|Detection means, compositions and methods for modulating synovial sarcoma cells|

---

EP3942023A1|2019-03-18|2022-01-26|The Broad Institute, Inc.|Compositions and methods for modulating metabolic regulators of t cell pathogenicity|

---

EP3946382A1|2019-04-04|2022-02-09|UMC Utrecht Holding B.V.|Modified immune receptor constructs|

---

WO2020210678A1|2019-04-12|2020-10-15|Novartis Ag|Methods of making chimeric antigen receptor-expressing cells|

---

TW202106704A|2019-04-26|2021-02-16|美商艾洛基因醫療公司|Rituximab-resistant chimeric antigen receptors and uses thereof|

---

BR112021021349A2|2019-04-26|2022-02-01|Allogene Therapeutics Inc|Methods of manufacturing cartalogenic cells|

---

AU2020265741A1|2019-05-01|2021-11-25|Editas Medicine, Inc.|Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods|

---

WO2020223571A1|2019-05-01|2020-11-05|Juno Therapeutics, Inc.|Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods|

---

EP3964238A1|2019-05-07|2022-03-09|Gracell BiotechnologiesCo., Ltd.|Bcma-targeting engineered immune cell and use thereof|

---

KR20220017914A|2019-05-07|2022-02-14|그라셀 바이오테크놀로지스컴퍼니, 리미티드|Engineered immune cells targeting BCMA and uses thereof|

---

WO2020236967A1|2019-05-20|2020-11-26|The Broad Institute, Inc.|Random crispr-cas deletion mutant|

---

WO2020243371A1|2019-05-28|2020-12-03|Massachusetts Institute Of Technology|Methods and compositions for modulating immune responses|

---

WO2020239866A1|2019-05-28|2020-12-03|Miltenyi Biotec B.V. & Co. KG|Method for generation of genetically modified t cells|

---

WO2021016606A1|2019-07-24|2021-01-28|Eureka Therapeutics, Inc.|Chimeric antigen receptor t cells and uses thereof|

---

WO2021030627A1|2019-08-13|2021-02-18|The General Hospital Corporation|Methods for predicting outcomes of checkpoint inhibition and treatment thereof|

---

WO2021041922A1|2019-08-30|2021-03-04|The Broad Institute, Inc.|Crispr-associated mu transposase systems|

---

WO2021047804A1|2019-09-11|2021-03-18|Miltenyi Biotec B.V. & Co. KG|In vitro method for transduction of t cells in the presence of malignant cells|

---

WO2021113116A1|2019-12-03|2021-06-10|University Of Massachusetts|Compositions and methods for optogenetic immunotherapy|

---

CN113087805A|2019-12-31|2021-07-09|华东师范大学|Preparation and application of chimeric antigen receptor T cell of co-expression immune regulatory molecule|

---

WO2021146147A1|2020-01-13|2021-07-22|Nkarta, Inc.|Bcma-directed cellular immunotherapy compositions and methods|

---

WO2021156277A1|2020-02-04|2021-08-12|Miltenyi Biotec B.V. & Co. KG|Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens|

---

WO2021163618A1|2020-02-14|2021-08-19|Novartis Ag|Method of predicting response to chimeric antigen receptor therapy|

---

WO2021173985A2|2020-02-27|2021-09-02|Novartis Ag|Methods of making chimeric antigen receptor-expressing cells|

---

WO2021173995A2|2020-02-27|2021-09-02|Novartis Ag|Methods of making chimeric antigen receptor-expressing cells|

---

WO2021183761A1|2020-03-11|2021-09-16|The Trustees Of The University Of Pennsylvania|Methods and composition for gene delivery using an engineered viral particle|

---

CN113402612A|2020-03-17|2021-09-17|西比曼生物科技（香港）有限公司|Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof|

---

WO2021212069A1|2020-04-17|2021-10-21|City Of Hope|Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies|

---

EP3916388A1|2020-05-27|2021-12-01|Miltenyi Biotec B.V. & Co. KG|Reagents for detection of chimeric antigen receptor cells|

---

EP3915578A4|2020-05-28|2021-12-01|Miltenyi Biotec Bv & Co Kg|Chimeric antigen receptor with a spacer comprising c2-set ig-like domains|

---

US20220002424A1|2020-06-12|2022-01-06|Nkarta, Inc.|Genetically modified natural killer cells for cd70-directed cancer immunotherapy|

---

WO2021260186A1|2020-06-26|2021-12-30|Juno Therapeutics Gmbh|Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods|

---

EP3964585A1|2020-09-03|2022-03-09|Miltenyi Biotec B.V. & Co. KG|Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US201361765585P| true| 2013-02-15|2013-02-15|

---